Southern Methodist University

SMU Scholar
Faculty Journal Articles and Book Chapters

Faculty Scholarship

2020

Patent Eligibility and Investment
David O. Taylor
Southern Methodist University, Dedman School of Law
Author ORCID Identifier:
https://orcid.org/0000-0001-6531-6100

Recommended Citation
David O. Taylor, Patent Eligibility and Investment, 41 CARDOZO L. REV. 2019 (2020)

This document is brought to you for free and open access by the Faculty Scholarship at SMU Scholar. It has been
accepted for inclusion in Faculty Journal Articles and Book Chapters by an authorized administrator of SMU
Scholar. For more information, please visit http://digitalrepository.smu.edu.

PATENT ELIGIBILITY AND INVESTMENT
David O. Taylort

Have the Supreme Court's recent patent eligibility cases changed the behavior of
venture capital and private equity investment firms, and if so how? This Article
provides empirical data about investors' answers to those important questions.
Analyzing responses to a survey of475 investors atfirms investing in various industries
and at various stages offunding, this Article explores how the Court's recent cases have
influenced these firms' decisions to invest in companies developing technology. The
survey results reveal investors' overwhelming belief that patent eligibility is an
important consideration in investment decisionmaking, and that reduced patent
eligibility makes it less likely theirfirms will invest in companies developing technology.
According to investors, however, the impact differs between industries. For example,
investors predominantly indicated no impact or only slightly decreased investments in
the biotechnology, medical device, and pharmaceutical industries. The data and these
findings (as well as others described in the Article) provide critical insight, enabling
evidence-based evaluation of competing arguments in the ongoing debate about the
need for congressional intervention in the law ofpatent eligibility. And, in particular,
they indicate reform is most crucial to ensure continued robust investment in the
development of life science technologies.
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INTRODUCTION

In a series of recent cases the Supreme Court significantly altered the
landscape of patent law.I Indeed, the Court has "embarked upon a drastic
and far-reaching experiment in patent eligibility standards."2 Numerous
inventors, scientists, lawyers, lawyer groups, companies, industry groups,
professors, and judges have decried this sea change in patent law.3 They
have highlighted not only critical flaws in the Supreme Court's analyses,
but also the perverse impact of the Court's new eligibility standard.4 The
new standard, for example, has required lower courts to make
determinations of ineligibility that judges themselves recognize as

See generally Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Ass'n for Molecular
Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013); Mayo Collaborative Servs. v. Prometheus

Labs., Inc., 566 U.S. 66 (2012); Bilski v. Kappos, 561 U.S. 593 (2010).
2 Jeffrey A. Lefstin et al., FinalReport of the Berkeley Centerfor Law & Technology Section 101
Workshop: AddressingPatentEligibility Challenges, 33 BERKELEY TECH. L.J. 551, 554 (2018).
3

For summaries of criticisms, see generally JOHN R. THOMAS, CONG. RESEARCH SERV., 7-

5700, PATENTABLE SUBJECT MATTER REFORM (2017); U.S. PATENT & TRADEMARK OFFICE, PATENT
ELIGIBLE SUBJECT MATTER: REPORT ON VIEWS AND RECOMMENDATIONS FROM THE PUBLIC (2017).
4 See, e.g., AM. INTELLECTUAL PROP. LAW ASS'N, AIPLA LEGISLATIVE PROPOSAL AND REPORT
ON PATENT ELIGIBLE SUBJECT MATTER (2017); Letter from Donna P. Suchy, Section Chair, Am. Bar
Ass'n, Section of Intellectual Prop. Law, to the Honorable Michelle K. Lee, Under Sec'y of
Commerce for Intellectual Prop. & Dir. of the U.S. Patent & Trademark Office (Mar. 28, 2017);
INTELLECTUAL PROP. OWNERS ASS'N, PROPOSED AMENDMENTS TO PATENT ELIGIBLE SUBJECT
MATTER UNDER 35 U.S.C. § 101 (2017).
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incorrect, particularly in cases of biotechnology.5 Moreover, the standard

has created confusion and lacks administrability.6
The most significant concern with the Supreme Court's new
eligibility standard is that it has negatively impacted investment in the
development of technology, in the sense that it has reduced investment in
inventive activities in critically important industries, like biotechnology.7
The change in the law represents a "drastic and far-reaching experiment,"
in particular, because of the lack of certainty regarding the full extent of
that impact. And to some degree the lack of certainty cannot be
eliminated. For example, if investors have reduced investments in certain

industries, no one can say for sure what inventions were delayed, or,
worse, what inventions simply were not and will not be invented. No one
knows, for example, whether the Court's decisions have delayed or
altogether prevented the development of medicines and medical

procedures.8
There have been signals, however, of the likelihood of these
devastating consequences. The case of Ariosa Diagnostics, Inc. v.
Sequenom, Inc. represents perhaps the best example of how the Supreme
Court's new standard denies eligibility for inventions in critically
important fields.9 In 1996, long before the Supreme Court's recent cases,

two researchers discovered that a pregnant woman's bloodstream

5 See, e.g., Ariosa Diagnostics, Inc. v. Sequenom, Inc., 809 F.3d 1282, 1287 (Fed. Cir. 2015)
(Lourie, J., concurring in the denial of en banc rehearing) ("In sum, it is unsound to have a rule that
takes inventions of this nature out of the realm of patent-eligibility on grounds that they only claim
a natural phenomenon plus conventional steps, or that they claim abstract concepts. But I agree
that the panel did not err in its conclusion that under Supreme Court precedent it had no option
other than to affirm the district court.").
6

See David O. Taylor, ConfusingPatentEligibility, 84 TENN. L. REV. 157, 227 (2016) ("Beyond

confusing relevant policies and doctrines, the current approach to determining patent eligibility
lacks administrability.").
7

See, e.g., Hallie Wimberly, The Changing Landscape of PatentSubject MatterEligibility and

Its Impact on Biotechnological Innovation, 54 Hous. L. REV. 995 (2017) ("This roadblock to
intellectual property protection for biotechnological inventions, due both to the recent restrictions
and to the uncertain legal standard, may slow growth of the industry that relies heavily on
investment.").
8 There have been attempts in the past to identify the proportion of inventions that would not
be invented absent patent protection. See, e.g., Edwin Mansfield, Patents and Innovation: An
EmpiricalStudy, 32 MGMT. SCI. 173 (1986). To my knowledge, no one has conducted such a study
with respect to the Supreme Court's eligibility cases.
9 Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).
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includes genetic material from her unborn baby.10 In light of this
discovery, the researchers used known laboratory techniques to create a
method to detect this genetic material.ii This genetic material, in turn,
could be used to identify fetal characteristics such as gender as well as fetal

abnormalities such as Down's syndrome.12 This invention avoided risks
associated with prior techniques to identify fetal characteristics, namely
taking samples from the fetus or placenta. 13 The inventors sought and
obtained a patent for their invention. 14 In 2015, however, the U.S. Court
of Appeals for the Federal Circuit invalidated the patent using the
Supreme Court's recently-developed, heightened standard for patent

eligibility. 15
The Federal Circuit, which hears all appeals in patent cases, first
concluded that the existence of fetal genetic material in maternal blood is
a natural phenomenon, and that the claimed method described in the
patent was directed to this natural phenomenon.16 Then, the court

concluded that the claimed method did not include any "inventive
concept" transforming this natural phenomenon into a patent-eligible
invention.17 In particular, the court highlighted that the claimed
invention involved merely routine, well-understood, conventional
techniques to detect the natural phenomenon. 18 As a result, the court
invalidated the patent for failing to disclose patent-eligible subject
matter. 19

Judge Linn concurred, but his opinion condemned the Supreme
Court's standard that required the court's finding of ineligibility.2o He
joined the court's opinion only because he felt bound by the Supreme

Court's standard.21 He lamented that that standard required him to
deprive "a meritorious invention from the patent protection it deserves
Id. at
1 Id.
12 Id. at
13 Id. at
14 Id.
15 Id.
16 Id. at
17 Id. at
18 Id. at
19 Id. at
20 Id. at
21 Id. at
1o

1373.
1373, 1381 (Linn, J., concurring).
1373.

1376.
1376-77.
1377.

1378.
1380-81 (Linn,

1380.

J., concurring).
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and should have been entitled to retain."22 In particular, Judge Linn
criticized the second part of the standard, the requirement of an
"inventive concept," which discounts "seemingly without qualification"
any conventional or obvious steps in a process. 23 Judge Linn pointed out
how this aspect of the standard conflicts with prior Supreme Court
precedent, in particular Diamond v. Diehr, which held that "a new
combination of steps in a process may be patentable even though all the
constituents of the combination were well-known and in common use

before the combination was made."24
Judge Linn also highlighted how meritorious the invention was. It
eliminated the need for invasive prenatal methods to detect genetic
material, which presented health risks to the mother and unborn baby,
were time consuming, and required expensive equipment.25 It
represented a paradigm shift to non-invasive prenatal diagnoses that

presented fewer risks and a more dependable rate of abnormality
detection.26 He made clear his belief that Sequenom's patent "claims a
new method that should be patent eligible."27 In particular, he explained,
"[t]he new use of the previously discarded maternal plasma to achieve
such an advantageous result is deserving of patent protection."28 Notably,
Judge Linn also highlighted how use of a traditional standard would have
resulted in a finding of patent eligibility for the invention, because the
invention "effectuate[d] a practical result and benefit not previously
attained."29 But for the Supreme Court's standard, he saw "no reason, in
policy or statute, why this breakthrough invention should be deemed
patent ineligible."30

22 Id.
23 Id.

26

Id. (quoting Diamond v. Diehr, 450 U.S. 175, 188 (1981)).
Id. at 1381.
Id.

27

Id.

24

25

28

29

Id.
Id. (alteration in original).

30 Id. Other judges similarly condemned the Supreme Court's standard when the Federal

Circuit denied a petition for en banc rehearing in the same case. See Ariosa Diagnostics, Inc. v.
Sequenom, Inc., 809 F.3d 1282 (Fed. Cir. 2015) (per curiam order denying en banc rehearing).
Judges Lourie and Moore, for example, similarly expressed their view that "neither of the traditional
preclusions of laws of nature or of abstract ideas ought to prohibit patenting of the subject matter
in this case." Id. at 1284 (Lourie,

J.,

concurring). They explained that "methods that utilize laws of
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Building upon judges' views that they are bound by the Supreme

Court's standard and their concerns that that standard is having
devastating consequences, various groups believe the situation is so
untenable that they have proposed ways Congress might overturn that
standard.31 Others, however-particularly large, established, software-

and Internet-focused companies and their representatives-disagree.32
They effectively ask: To what extent have the Court's cases shifting
eligibility law actually impacted decisions to invest in the development of
technology? Moreover, exactly how have these cases actually impacted
investment decisions? And to the extent these cases have had a significant
impact on investment decisions, has that impact proven to be positive or

negative in the sense of increased or decreased investment?
Existing literature provides surprisingly little data even to begin to

answer these questions.33 Indeed, I have been unable to identify any
survey asking investors to identify how changes to patent eligibility law
have impacted their investment decisions. And, make no mistake, these
questions are fundamental, and the accuracy of their answers is
important. Answers to these questions, for example, will either support
congressional intervention in the law of patent eligibility or counsel
against it. Thus, the questions ought to be asked and-more

nature do not set forth or claim laws of nature." Id. at 1285. Likewise, "steps that involve machines,
which are tangible, steps that involve transformation of tangible subject matter, or tangible
implementations of ideas or abstractions should not be considered to be abstract ideas." Id. They
recognized that others have said "that a crisis of patent law and medical innovation may be upon
us, and there seems to be some truth in that concern." Id. "In sum, it is unsound to have a rule that
takes inventions of this nature out of the realm of patent-eligibility on grounds that they only claim
a natural phenomenon plus conventional steps .....

Id. at 1287. Judge Dyk also concurred,

expressing that he shared the concerns expressed by others. Id. at 1288-90 (Dyk,

J.,

concurring).

Judge Newman dissented, agreeing with her colleagues that the case was wrongly decided but
disagreeing that the incorrect decision was required by Supreme Court precedent. Id. at 1293-94
(Newman,
31

J.,

dissenting).

See supra note 4. I served as a member and the Reporter of the Patentable Subject Matter

Task Force of the American Intellectual Property Law Association.
32

See, e.g., WILLIAM G. JENKS, COMMENTS OF THE INTERNET ASSOCIATION AND THE

COMPUTER & COMMUNICATIONS INDUSTRY ASSOCIATION REGARDING THE LEGAL CONTOURS OF
SUBJECT

MATTER

ELIGIBILITY

(PART

2)

(2017),

https://www.uspto.gov/sites/default/files/

documents/RT2%20Comments%20the%20Internet%20Association%20and%20the%
20Computer%20%26%2OCommunications%20Industry%2OAssociation.pdf

GJ6C-NLKC].
33 See infra Section V.A.

[https://perma.cc/
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importantly-answered by reference to hard data rather than gut feeling
or prognostication.34 Quite literally, future innovation-lifesaving
innovation-hangs in the balance.
And so that is exactly what I have done: gathered data to help begin
the process of identifying accurate answers to these questions about the
Supreme Court's impact on decisions to invest in the development of
technology. In particular, I have conducted a survey of 475 venture capital
and private equity investors to study the impact of the Court's eligibility
cases on their firms' decisions to invest in companies developing
technology. This survey is the first of its kind, and the data it has provided

is sorely needed.
The results of the survey provide critical insights into the impact of
the Supreme Court's eligibility cases. In this Article, I present detailed
results of the survey and identify and consider four principal findings.
The first relates to the absolute and relative importance of patent
eligibility with respect to investor decisionmaking. The second correlates
reduced eligibility with particular investment behaviors in particular
industries. The third provides more specific insight into the potential
causal connection between the Supreme Court's eligibility cases and
particular changes in investment behavior. And the fourth identifies a
correlation between investors' knowledge regarding the Court's eligibility
cases (what I refer to as eligibility knowledge) and changes in investment

behavior.
Regarding the first principal finding,35 the investors who responded
to the survey overwhelmingly believe patent eligibility is an important
consideration when their firms decide whether to invest in companies
developing technology. Indeed, overall, 74% of the investors agreed that
patent eligibility is an important consideration in firm decisions whether
to invest in companies developing technology; only 14% disagreed.
Likewise, investors reported that reduced patent eligibility for a
technology makes it less likely that their firm will invest in companies
developing that technology. For example, overall 62% of the investors
agreed that their firms were less likely to invest in a company developing
technology if patent eligibility makes patents unavailable, while only 20%

34 Cf Mark A. Lemley, Faith-BasedIntellectual Property, 62 UCLA L. REv. 1328, 1336 (2015)
(lamenting that "[p]articipants on both sides of the IP debates are increasingly staking out positions
that simply do not depend on evidence at all").
35 See infra Section

IV.A.
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disagreed. These results, while perhaps not surprising, nonetheless
confirm one of the central premises upon which the patent system rests:
that patents help to spur investment in development of technology. The
availability of patents, however, was not the most important
consideration to the investors. The quality of a target company's people
ranked as most important, followed by the quality of the company's
technology and the size of the potential market for the technology. By one
metric, investors deemed the availability of U.S. patent protection to be
only slightly less important than first-mover advantage; by another
metric, it was deemed slightly more important. Thus, the first principal
finding is that patent eligibility is an important factor-albeit certainly
not the most important factor-in investment decisions.
The second principal finding36 is that reduced patent eligibility
correlates with particular investment behaviors in particular industries.
Investors overwhelmingly indicated, for example, that the elimination of
patents would either not impact their firms' decisions whether to invest
in companies or only slightly decrease investments in companies
developing technology in the construction (89%), software and Internet
(80%), transportation (84%), energy (79%), and computer and electronic
hardware (72%) industries. But investors, by contrast, overwhelmingly
indicated that the elimination of patents would either somewhat decrease
or strongly decrease their firms' investments in the biotechnology (77%),
medical device (79%), and pharmaceutical industries (73%). Thus,

according to these investors, on average each industry would see reduced
investment, but the impact on particular industries would be different.
And the life sciences industries are the ones most negatively affected.
The third principal finding37 is that the Supreme Court's eligibility
cases have impacted many firms' investments and, more significantly
going forward, the firms' investment behaviors. Almost 40% of the
investors who knew about at least one of the Court's eligibility cases
indicated that the Court's decisions had somewhat negative or very
negative effects on their firms' existing investments, while only about 15%
of these investors reported somewhat positive or very positive effects. On
a going-forward basis, moreover, almost 33% of the investors who knew
about at least one of the Court's eligibility cases indicated that these cases
affected their firms' decisions whether to invest in companies developing
36
37

See infra Section IV.B.
See infra Section IV.C.
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technology. These investors reported primarily decreased investments,
but also shifting of investments between industries. In particular they
identified shifting of investments out of the biotechnology, medical

device, pharmaceutical, and software and Internet industries.
The fourth principal finding38 is that investors familiar with the
Supreme Court's eligibility cases indicated different changes in firm
investment behavior as compared to investors without this familiarity. As
discussed above, about 33% of investors with this familiarity reported that
these cases impacted their firms' investment behavior, with these
investors reporting shifting of investments away from the software and
Internet industry along with the biotechnology, medical device, and
pharmaceutical industries. Investors without familiarity with these cases,
by contrast, overwhelmingly reported that the decreased availability of
patents since 2009 (prior to the Supreme Court's eligibility cases) has not
impacted their firms' changes in investment behavior. Indeed, a full 95%
indicated no impact on any change in their firms' investments. Moreover,
investors without familiarity with these cases indicated more often, as
compared to investors with familiarity, that their firms have shifted
investments into the software and Internet industry as compared to all
other industries. In short, eligibility knowledgeable investors report the
Supreme Court's cases have resulted in reduced investment in software
and the Internet, while unknowledgeable investors report increased
investment in software and the Internet over the same time period. As
investors transition from unknowledgeable to knowledgeable (once they
learn about the Court's cases and their impact on patent eligibility),
investment in software and the Internet will seemingly decrease.
The results of the survey provide critical data for an evidence-based
evaluation of competing arguments in the ongoing debate about the need
for congressional intervention in the law of patent eligibility.39
Proponents of reform may tout the results of the survey as representing a
clarion call for reform.40 The best that can be said by those that prefer the

38
39

See infra Section IV.D.
See John M. Golden et al., The Path ofIP Studies: Growth, Diversification, and Hope, 92 TEX.

L. REv. 1757, 1759 (2014) ("IP legal studies have entered a new period of very substantial empirical
scholarship, a period that might enable more precise and accurate policy prescriptions than ever
before.").
40

See infra Section V.B.
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status quo is that most investors do not report changing their investment
decisionmaking based upon the Supreme Court's eligibility decisions.41 A
significant part of this group of investors, however, represents those
uninformed about the Court's cases. The reality is that the results of the
survey highlight the importance of patent eligibility and the negative
impact of the Supreme Court's eligibility cases generally on investment,
but particularly in the most important areas of technological
development in terms of its impact on public health: the biotechnology,
medical device, and pharmaceutical industries, which collectively I refer
to as the life sciences industries. That said, it is important to highlight that
the results show the Court's decisions have negatively impacted each and
every area of technological development studied. And, as a consequence,
the results do support the idea that the time has come for Congress to at
least consider overturning the Supreme Court's new eligibility standard
to prevent additional lost investment in technological development in the
United States.42 Indeed, given the results of the survey, it seems likely that
the Supreme Court's eligibility decisions have resulted in lost investment
in the life sciences that has delayed or altogether prevented the

development of medicines and medical procedures.
I have organized the Article into five main Parts. In Part I, I explain
the need for a survey of this type by highlighting the recent development
of the law governing patent eligibility, the criticisms of its current state,
and the absence of data answering basic questions about the impact of the
Supreme Court's decisions in the area of patent eligibility. In Part II, I
describe my hypothesis and the survey methodology used to test that
hypothesis. In Part III, I explore the demographics of the respondents to
the survey and compare the respondents to the non-respondents to assess
the extent to which they are representative or reflect selection bias. In Part
IV, I study the results of the survey, identifying and exploring the
ramifications of the four principal findings I have already summarized.
In Part V, I identify where the results of this survey fit within the existing
literature and recognize limitations on the survey's results and findings,
before briefly concluding.

41
42

See infra Section V.C.
See generallyDavid O. Taylor,AmendingPatentEligibility,50 U.C. DAVISL. REv.2149 (2017)

(evaluating various approaches to amending the patent statute).
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THE LAW OF PATENT ELIGIBILITY

To understand the need for a survey of the type I conducted, one
must understand recent judicial developments in the law governing
patent eligibility, primarily its recent changes and its present state. Then

one must understand the significant criticism engendered by the present
state of the law, along with gaps in the evidence underlying some of the
criticism.

A.

Recent Judicial Developments

While the patent statute by its terms extends eligibility to "any new
and useful process, machine, manufacture, or composition of matter, or
any new and useful improvement thereof,"43 the Supreme Court has long
held that eligibility does not encompass laws of nature, natural

phenomena, and abstract ideas. 44
These judicially recognized exceptions to the statutory text have
been the subject of numerous Supreme Court decisions over the last
several decades, including eight since 1972.45 The distribution of these
eight cases, however, has been almost perfectly bimodal. Between 1972
and 1981 the Supreme Court decided the first four of these eight cases,

and between 2010 and 2014 the Court decided the last four. In between

43 35 U.S.C. § 101 (2018).
44

See Parker v. Flook, 437 U.S. 584, 598 (1978) (Stewart, J., dissenting) ("It is a commonplace

that laws of nature, physical phenomena, and abstract ideas are not patentable subject matter.");

Mackay Radio &Tel. Co. v. Radio Corp. of Am., 306 U.S. 86,94 (1939) ("[A] scientific truth, or the
mathematical expression of it, is not patentable invention .... ); Rubber-Tip Pencil Co. v. Howard,

87 U.S. (20 Wall.) 498, 507 (1874) ("An idea of itself is not patentable .... ); Le Roy v. Tatham, 55
U.S. (14 How.) 156, 175 (1853) ("[A] principle is not patentable.... Nor can an exclusive right exist
to a new power, should one be discovered in addition to those already known. Through the agency
of machinery a new steam power may be said to have been generated. But no one can appropriate
this power exclusively to himself, under the patent laws. The same maybe said of electricity, and of
any other power in nature, which is alike open to all, and may be applied to useful purposes by the
use of machinery.").
45

Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Ass'n for Molecular Pathology v. Myriad

Genetics, Inc., 569 U.S. 576 (2013); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S.

66 (2012); Bilski v. Kappos, 561 U.S. 593 (2010); Diamond v. Diehr, 450 U.S. 175 (1981); Diamond
v. Chakrabarty, 447 U.S. 303 (1980); Parker v. Flook, 437 U.S. 584 (1978); Gottschalk v. Benson,
409 U.S. 63 (1972).
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those two time periods-indeed in 1982, just one year after the fourth of
the eight decisions-Congress established a new court, the U.S. Court of
Appeals for the Federal Circuit, and vested it with nearly exclusive
jurisdiction over appeals in patent cases. 46 Then, between 1982 and 2010
the Supreme Court effectively deferred to the Federal Circuit's
understanding and application of the judicially recognized exceptions to
eligibility; the Court did not decide one case on the topic of patent
eligibility during this twenty-eight-year period.
The Federal Circuit, however, repeatedly interpreted and applied the
law governing patent eligibility during that period. Moreover, largely
consistent with most of the Supreme Court's pronouncements in this area
of the law prior to 1982, the Federal Circuit enforced a rather permissive

standard that ensured broad eligibility. Between 1994 and 2008, for
example, that standard permitted a claimed invention to be eligible for
patenting so long as it fell within one of the statutory categories (a
"process, machine, manufacture, or composition of matter," or an
"improvement thereof") and did not fall within one of the judicially
created exceptions ("laws of nature, natural phenomena, and abstract
ideas"), where the latter did not occur if the claimed invention was a
"practical application of an abstract idea" such that it produced a "useful,
concrete, and tangible result."47 In 2006, however, some members of the

Supreme Court viewed this standard as too lax; in a dissent from a
dismissal of a case in which the Court granted certiorari to the Federal
Circuit, they expressed the view that "this Court has never made such a
statement [that an abstract idea is one that does not produce a useful,
concrete, and tangible result] and, if taken literally, the statement would
cover instances where this Court has held the contrary."48 No doubt as a
result, in 2008 the Federal Circuit changed its interpretation of the
judicially created exceptions, adopting instead a "machine-or-

46

Federal Courts Improvement Act of 1982, Pub. L. No. 97-164, 96 Stat. 25.

In re Alappat, 33 F.3d 1526, 1544 (Fed. Cir. 1994); State St. Bank & Tr. Co. v. Signature Fin.
Grp., 149 F.3d 1368, 1373 (Fed. Cir. 1998), abrogated by Bilski v. Kappos, 561 U.S. 593 (2010);
AT&T Corp. v. Excel Commc'ns, Inc., 172 F.3d 1352, 1356 (Fed. Cir. 1999).
48 Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 136 (2006) (Breyer, J.,
47

dissenting from dismissal of the writ of certiorari as improvidently granted).

2020 ]

PATENT ELIGIBILITY AND INVESTMENT

2033

transformation test"49 that asked whether the claimed invention "is tied
to a particular machine or apparatus" or "transforms a particular article
into a different state or thing."so This test, however, also ultimately proved
to be too lax for the Supreme Court.
The Supreme Court reentered the scene in 2010 to review the
Federal Circuit's decision adopting the machine-or-transformation test
and, ultimately, rejected that test as the exclusive basis to determine

patent eligibility.si But the Court did so without identifying any standard
whatsoever for determining when a claimed invention falls within a
judicial exception.52 In two subsequent cases, the Court finally did

identify a new governing standard; it created a two-part test for
determining patent eligibility.33 That test significantly increased the
likelihood that a claimed invention would be found ineligible. It requires,
first, determining whether a claim is directed to one of the patentineligible concepts (laws of nature, natural phenomena, and abstract
ideas).54 If so, one must ask whether elements in the claim transform the
nature of the claim into a patent-eligible application of the otherwise
ineligible concept, a question the Court describes as a search for an
"inventive concept-i.e., an element or combination of elements that is
sufficient to ensure that the patent in practice amounts to significantly
more than a patent upon the ineligible concept itself."55
This standard represents a sea change in patent law because it
requires an inventive application of a newly discovered law of nature,
natural phenomenon, or abstract idea-directly contrary to the Court's
historical standard requiring a mere practical application of any such
discovery.56 As a result, for the Court it is apparently not enough to obtain
a patent for a scientist to make a new discovery (e.g., the cure to cancer)

49

In re Bilski, 545 F.3d 943, 959-60 (Fed. Cir. 2008) (en banc) (concluding "that the 'useful,

concrete and tangible result' inquiry is inadequate" and adopting a "machine-or-transformation
test").
5o

51

Id. at 954.
Seegenerally Bilski v. Kappos, 561 U.S. 593 (2010).

52 Id.
53 See generally Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs.
v. Prometheus Labs., Inc., 566 U.S. 66 (2012).
54 Alice, 573 U.S. at 217-18.
55 Id. (internal quotation marks and brackets omitted) (quoting Mayo, 566 U.S. at 72-73).

56 See generally Jeffrey A. Lefstin, Inventive Application:A History, 67 FLA. L. R~v. 565 (2015).
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and disclose how to apply that discovery to advance the state of the world
(e.g., treat patients using the cure). There must be a disclosure of how to
apply the new discovery in a new way. This is a double novelty
requirement. In short, the Supreme Court has shifted the law of patent
eligibility significantly since 2010, making it much more difficult to prove
eligibility. The Federal Circuit's invalidation of the patent in Ariosa
Diagnostics,Inc. is just one example.57
B.

Criticisms of the Supreme Court's Approach

Many, including myself, have criticized the Supreme Court's patent
eligibility decisions and, in particular, this new two-part test and the
search for an "inventive concept."58 I, for example, have argued that this
test "reflects a lack of understanding of the relevant statutory provisions,
precedent, and policies already undergirding the patent statute."59 I have
also argued that the two-part test lacks administrability because "[i]t is
exceedingly difficult to understand whether a[] patent examiner or a
court should find subject matter eligible for patenting given the
overarching test for eligibility articulated by the Supreme Court."60 But

other criticisms have been even more devastating. Indeed, in Ariosa
Diagnostics,Inc., multiple Federal Circuit judges went so far as to say that
the Supreme Court's test results in incorrect findings of ineligibility.61
Various groups, moreover, are convinced that the Court's test is so
problematic and its impact so negative in terms of reducing investment

57

Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).

58 See generally Lefstin, supra note 2 (discussing widespread agreement over such criticism).

59 Taylor, supra note 6, at 244-45.
60
61

Id. at 227.
See, e.g., Ariosa Diagnostics, Inc. v. Sequenom, Inc., 809 F.3d 1282, 1287 (Fed. Cir. 2015)

(Lourie, J., concurring in the denial of en banc rehearing) ("In sum, it is unsound to have a rule that
takes inventions of this nature out of the realm of patent-eligibility on grounds that they only claim
a natural phenomenon plus conventional steps, or that they claim abstract concepts. But I agree
that the panel did not err in its conclusion that under Supreme Court precedent it had no option
other than to affirm the district court."); Ariosa Diagnostics, 788 F.3d at 1381 (Linn, J., concurring)
(finding claims ineligible but stating that "[b]ut for the sweeping language in the Supreme Court's
Mayo opinion, I see no reason, in policy or statute, why this breakthrough invention should be
deemed patent ineligible").
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in technological development that they are considering ways Congress
might amend the patent statute to overturn that test. 62
These groups have proposed specific statutory language their
members believe set forth workable and appropriate standards for courts
to use to determine patent eligibility. But to convince Congress to amend
the patent statute to include one of these standards, these groups probably
need more than simple arguments related to confusion, arguments of lack
of administrability, and examples of incorrect findings of ineligibility.63
What they need is evidence-data-showing how the Supreme Court's
decisions, and in particular the two-part test for determining eligibility,
have negatively impacted investment in the development of technology.
Indeed, in my recent article addressing patent eligibility, given the lack of
relevant data,64 I was forced to argue that the "risk of underinvestment in
research and development" gave reason to consider encouraging
Congress to amend the patent statute. 65
Data is needed to answer the following types of questions: Has the
Supreme Court's change in the law of patent eligibility changed
investment in the development of technology? If so, how? Is there now
less overall investment in the development of technology? Is there less
investment in the development of technology in certain industries, but
more in others? How has the Court's eligibility decisions impacted
venture capital investment? Have the Court's decisions increased
companies' investments in the development of technologies protected by

trade secrets as opposed to patents? Have investment dollars dried up in
certain areas of science and technology? Or have the Court's decisions

had no discernable impact on investment decisions? As I have
mentioned, existing literature provides surprisingly little data even to
begin to answer these questions.66

62

See sources cited supra note 4.

63

Of course, these groups have plenty of ammunition in this regard. See sources cited supra

note 4.
64
65

66

See infra Section I.C.
Taylor, supra note 6, at 163 (emphasis added).
See infra Section I.C.
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Previous Studies and Surveys

Previous studies and surveys more broadly addressed the role of
patents with respect to investment in research and development.
Maureen Ohlhausen, at the time a Commissioner of the Federal Trade
Commission, recently analyzed and summarized much of this
literature-both theoretical and empirical literature addressing the
relationship between patents and innovation.67 Notably, the present
survey supports conclusions consistent with the majority of this
literature, while focusing attention on the particular doctrine of patent
eligibility.
Commissioner Ohlhausen first summarized the principal findings
of various econometric studies. For example, she described how
"[s]urveys reveal that patents contribute to incentives to invest, most
acutely in the bio-pharmaceutical and medical device fields but elsewhere
to varying degrees as well."68 As support for this finding, she described,
among other things, "[a] host of... empirical work... find[ing] a
statistically significant relationship between patent strength and R&D
[(Research & Development)] investment."69 "[E]mpirical evidence that
patents drive innovation in pharmaceuticals," she reported, "is especially
strong."70 And, "[m]ore generally, there is evidentiary support for the
core proposition underlying the economic case for patents: investment in
R&D will be suboptimal if the investing firm has limited ability to
internalize the ensuing value."71 That said, she recognized that "the
econometric work to date is not unanimous in linking strong IP rights
and innovation."72As already described, consistent with the majority of
the econometric work, the present survey reveals that patents contribute
to incentives to invest in technological development generally, and in the

biomedical,

medical

device,

and

pharmaceutical

industries

in

particular.73
67 See generallyMaureen K. Ohlhausen, PatentRights in a Climate ofIntellectual PropertyRights
Skepticism, 30 HARV. J.L. &TECH. 103 (2016).
68 Id. at 125.
69 Id. at 128.
7o Id. at 130.

71
72

73

Id.

Id. at 131.
See generally infra PartIV.
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Some prior studies focused on particular industries. For example, a
study of venture-backed software firms explored the relationship between

patenting and investment in the software industry. 74 The data indicated
that "an increase of one in the total number of patents is related with an
increase of $2.7M in total investment, so that firms with patents received
about $10.7M more in total investment that those without."75 The data
suggested to the study's authors that "patents are valuable for the firms
that elect to obtain them, but this data does not exclude the possibility
(frequently discussed in the existing literature) that the transaction costs
those patents impose on third parties exceed the value they provide to the
firms that obtain them."76 Their work, moreover, "provides substantial
evidence that patenting, at least in [the software] industry, is an important
part of a well-organized operation, rather than a random or happenstance
occurrence."77 The present survey similarly highlights that reduced

patent eligibility has caused investors to report reduced incentive to
invest in the software industry. 78
Commissioner Ohlhausen also summarized the principal findings
of various surveys. After conceding the limited usefulness of surveys-in
part because "what people say they will do often differs from what they
will actually do"-she recognized that "there is reason to survey
innovators in an effort to determine which factors drive them to invest in
R&D."79 She highlighted two such surveys. In her view, these surveys'
"most important takeaway is that patents are the principal means of
protecting
innovations
in
certain
industries,
especially
in
pharmaceuticals but elsewhere too, and are of ancillary effectiveness
compared to other appropriation mechanisms in other industries."8o
One survey recorded the responses of 650 high-level R&D executives
to questions seeking to determine "those industries and technologies in
which patents are effective in preventing competitive imitation of a new

74 Ronald J. Mann & Thomas W. Sager, Patents, Venture Capital, and Software Start-ups, 36
RES. POL'Y 193 (2007).
75 Id. at 201.
76 Id. at 205.
77 Id. at 207.
78 See generally infra Sections IV.B., C.

79 Ohlhausen, supra note 67, at 134.
80

Id. at 134-35.
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process or product."81 The respondents revealed their view that patents
were generally the least effective of various mechanisms (specifically:
patents to prevent duplication, patents to secure royalty income, secrecy,
lead time, moving quickly down the learning curve, and sales or service
efforts) for protecting new methods, but had greater effect on protecting
new products.82 One exception was the drug industry, where a majority
of respondents rated patents as more effective than other means of
appropriation.83 The present survey did not separately address methods

and products. And it did reveal, contrary to this prior survey, that patents
are more important than trade secrecy in spurring investment in
technological development, and that patents are only slightly less
important or slightly more important than first-mover advantage.84 The
present survey, though, points in the same direction as the prior survey
in the sense that both highlight that in the pharmaceutical or drug
industry patents are more important than other factors in spurring
investment and preventing competitive imitation respectively. 85
Another survey tabulated the responses of 1,478 R&D labs and
sought similar (as compared to the previously highlighted survey)
information related to appropriation mechanisms.86 This survey found
that, of patents, secrecy, lead time advantages, and the use of
complementary marketing and manufacturing capabilities, "in no
industry [were] patents identified as the most effective appropriability
mechanism."87 Furthermore, "patents tend [ed] to be the least emphasized
by firms in the majority of manufacturing industries."88 In the medical
equipment and drugs industries, however, "patents [were] reported to be
effective for more than 50% of product innovations, and in special
purpose machinery, computers and autoparts, the effectiveness scores

81 Richard C. Levin et al., Appropriatingthe Returns from Industrial Research and Development,

3 BROOKINGS PAPERS ON ECON. ACTIVITY 783, 784 (1987).
82
83

84

85

Id. at 794-95.
Id. at 796.
See infra Section IV.A.2.
See infra Section IV.A.2.

86 Wesley M. Cohen et al., Protecting Their Intellectual Assets: Appropriability Conditions and

Why U.S. Manufacturing Firms Patent (or Not) (Nat'l Bureau of Econ. Research, Working Paper

No. 7552, 2000).
87 Id. at 9.
88 Id. at 1.
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range from 40% to 50% of product innovations."89 Moreover, as
highlighted by Commissioner Ohlhausen in her review of this study,90
large firms reported patents as the most effective appropriation
mechanism not just in the drug industry, but also in the (relatively narrow
industries of) toilet preparations, gum and wood chemicals,
pipes/values/oil field machinery, switchgear, and autoparts. 91 The
authors of the survey concluded that "patents [were] still not the
dominant mechanism in most industries for protecting product
innovations, [but] it now appears that they can be counted among the
major mechanisms of appropriation in a more sizable minority of
industries."92 Others analyzing the data gathered in this survey concluded
based on their own analysis that patents stimulate investment in R&D in
various industries, most prominently in the biotechnology, medical
device, and pharmaceutical industries, but also in the electronics and
semiconductor industries.93 The present survey again asks different
questions and reaches somewhat different results. According to the
present survey, patents similarly do not rank as the most important factor

in investment decisions in any industry.94 But in every industry they rate
as more important than trade secrecy and similar in importance to firstmover advantage.95 Finally, the two surveys both indicate that patents
stimulate investment in technological development in the biotechnology,
medical device, pharmaceutical, electronics, and semiconductor

industries.96
A third survey summarized by Commissioner Ohlhausen recorded
the responses of 1,332 early-stage technology companies to questions
addressing the role of patents in spurring innovation.97 Notably, 76% of
venture-backed companies reported that venture capital investors had

89

Id. at 9.

90

See Ohlhausen, supra note 67, at 136-37.

91

See Cohen, supra note 86, at 12.
Id. at 13.

92

93 Ashish Arora, Marco Ceccagnoli & Wesley M. Cohen, R&D and the Patent Premium, 26
INT'L J. INDUS. ORG. 1153, 1154, 1173 (2008).

96

See infra Section IV.A.
See infra Section IV.A.
See infra Section IV.A.

97

See Ohlhausen, supra note 67, at 140 (summarizing data reported in Stuart J.H. Graham et

94
95

al., High Technology Entrepreneursand the PatentSystem: Results of the 2008 Berkeley PatentSurvey,

24 BERKELEY TECH. L.J. 1255 (2009).
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indicated to the companies that patents were an important factor to their

funding decisions.98 As to particular industries, 85% of medical device
companies, 73% of biotechnology companies, and 60% of software
companies reported that venture capital investors considered patents
important.99 In the same survey, respondents indicated that in the

biotechnology industry, patents exceeded first-mover advantage, secrecy,
trademark, and copyright in importance to capture competitive
advantage from technological inventions.100 In the medical device
industry, patents exceed all of these mechanisms except first-mover
advantage.10, In the software industry, however, patents ranked the
lowest of all of these factors.1o2
Notably, the present survey directly asks venture capital and private
equity investors their views of the importance of patent eligibility to their
investment decisions, rather than relying upon indirect reports of their
views by early-stage technology companies. Regardless, in some ways the
results of the two surveys are consistent. Quite similar to the prior survey,
74% of the investors agreed that patent eligibility is an important
consideration when their firms decide whether to invest in companies
developing technology.io3 Similar too to the prior survey, agreement

among investors in the medical device and biotechnology industries
exceeded those in the software industry. In the present survey, 81% of
investors in the medical device industry, 79% in the biotechnology

industry, and 72% in the software and Internet industry considered
patent eligibility as important,104 compared to 85%, 73%, and 60%
respectively of the start-up companies in these industries in the prior
survey. 105
Regarding the relative importance of various factors, however, the
present survey somewhat differs from the prior survey. The two sets of
respondents agree that in the biotechnology industry patents exceed firstmover advantage, secrecy, trademark, and copyright protection in

98

Graham, supra note 97, at 1307.

Id.
loo Id. at 1290-91.
1 Id.
102 Id. at 1290-93.
103 See infra Section IV.A.1.
104 See infra Section IV.A.1.b.
99

105

See Graham, supra note 97, at 1290.
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importance (relating to the ability to capture competitive advantage from
technological inventions in the prior survey and to the investment
decisions in the present survey).106 But the present survey reveals the
same order of importance for the medical device and, most notably, the
software industry.107 While in the prior survey the software industry
patents ranked the lowest of all of the factors (first-mover advantage,
secrecy, trademark, copyright, and patents) in terms of importance to the
ability to capture competitive
advantage from technological
inventions,108 in the present survey the availability of U.S. patents ranks
the highest of all of these same factors in terms of importance to
investment decisionmaking.109
This difference between the surveys may reflect a difference between
the views of those working in early-stage technology companies and the
views of investors. That is, entrepreneurs may underestimate the
importance of patents to investors. If correct, this is an important finding,
and entrepreneurs will no doubt want to take note and adjust their efforts
to obtain patent protection for their inventions. It may, moreover, reflect
a difference between the views of those whose sole focus is software
development and investors who invest not only in software but also in
other industries. It may also reflect a difference between views regarding
patents as a means to capture competitive advantage from technological
inventions, and views regarding patents as a signal of increased
investment return both through competitive advantage and through
other means of capturing value. Investors, for example, may view patents
as a signal of the ability to obtain a higher return on investment through
the ability to exclude competitors from using the same technology. But
investors may also focus on patents as a signal of the ability to obtain a
higher return on investment in other ways, for example by differentiation
of the companies' technology in the marketplace, the ability of the
company to gain funding from other investors to further their
technological development and their intellectual property pursuits, the
ability of the target's principals to develop not just technology but also a
business plan, and the ability of the investors themselves to hedge their
investment against any value of the enterprise's intellectual property. Or,

106 Compare

id. at 1290-95, with infra Section IV.A.
IV.A.

107 See infra Section
108

Graham, supra note 97, at 1290.

109

See infra Section IV.A.1.b.
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of course, the difference could be explained by a combination of these or
other reasons.
In short, the survey I have conducted is one that was sorely needed.
As I have mentioned, multiple organizations have proposed ways to
amend the patent statute to overturn the Supreme Court's new patent
eligibility standard.1o All of these organizations include interested
individuals who believe that the Court's approach to patent eligibility has
negatively impacted the marketplace in which inventors create ideas and

bring those ideas to market. Prior generalized studies and surveys focused
on the importance of patents generally, without exploring the impact of
the recent Supreme Court decisions in the area of patent eligibility. Thus,
this survey begins to fill an important gap in the literature and addresses
a compelling research question that may have a significant impact on the
development of the law governing patent eligibility.
II.

HYPOTHESIS AND SURVEY METHODOLOGY

To begin to fill the gap in the existing literature related to the
Supreme Court's eligibility decisions and their impact or lack of impact
on investment in the development of technology, I conducted a survey of
venture capital firms and private equity investors. I structured the survey
to test my own hypothesis that the Court's decisions have had a
significant impact on the investment decisions of those firms, and in
particular has caused reduced investment in the life science industry.
Here I describe my hypothesis and the methodology I used to test it.

A.

Hypothesis Tested

I suspect that the Supreme Court's decisions in the area of eligibility
subject matter have had a significant impact on investment in the
development of technology and, moreover, that that impact has been
negative in terms of reducing investments generally, and in particular in
the life sciences industries. Thus, the hypothesis I sought to test is that the
Court's alteration of the law governing patent eligibility has impacted
decisionmaking with respect to investment in the development of

no See supra note 4.
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technology; that it had significant impact; and that the impact has been
negative in the sense of reducing investment.

B.

Methodology Employed

To gather relevant data, I conducted a survey of investors at venture

capital and private equity investment firms. I decided to survey firms
representing the various early stages of venture capital funding: seed,
early, middle, growth, expansion, and late stage investors. Moreover, I

decided that the survey would not focus on any one industry, but instead
more broadly span as many different industries as the venture capital and
private equity firms fund.
1.

Overview

In general, I asked two types of questions. First, I asked directly
whether the Supreme Court's decisions on patent eligibility have

impacted the surveyed entity's decisions to invest in companies
developing technology and, if so, how. This first type of question,
however, required familiarity with at least one of the Court's decisions.
Thus, second, I also asked more indirect questions related to the same
issue, for example by asking about any changes to decisions to invest in
companies over the relevant time period and whether those changes
relate to any decreased availability of patents.
2.

Detailed Summary

Here, I will provide a more detailed summary of the methodology I
employed in my survey.
a.

Who

I surveyed venture capitalist and private equity investors identified
in a commercial database provided by a company known as
"Massinvestor." I purchased from Massinvestor its 2017 national
database of venture capital and equity firms. Massinvestor advertises this
database as "the most comprehensive compilation of private capital
sources available. The Directory profiles investment firms in all 50 states,
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and represents a single, complete, authoritative resource."1 Notably,
Massinvestor identifies each of the people in its database as being
associated with investment firms of various types: "Venture Capitalists,
Private Equity firms, Family Offices, Angels, Incubators, Accelerators,
Merchant Banks, Fund of Funds, Economic Development Groups,
Venture Debt, Technology Transfer Offices, Secondary Purchasers, and
Corporate VCs. 1 1 2
I distributed the survey electronically by email to all 14,641 people

identified in the database. I used financial incentives to encourage
participation in the survey.11 3 Thanks to a grant from Microsoft
Corporation, I gave three progressive incentives. After conducting the
survey for some time with no incentive, I later advertised a drawing for a
Microsoft Surface, later fifteen dollar gift cards, and lastly twenty-five
dollar gift cards. After distributing the survey by email and offering these
incentives, I even later had research assistants place individual calls to
investors to offer incentives orally to encourage more participation.

b.

When, Where, and How

The survey asked for information on investment decisions. One part
of the survey asked for a comparison of investments between 2009 and
2017 when the survey was conducted. I picked 2009 as the first year to

survey because the Supreme Court decided its Bilski v. Kappos decision
in 2010. The survey asked for information after the Supreme Court's most

recent decision on eligibility; the Supreme Court decided Alice Corp. v.
CLS Bank Internationalin 2014, and the survey asked for information
through 2017 when the survey was conducted. The complete data set thus
covers about eight years, 2009 to 2017, both prior to the Supreme Court's

decision in Bilski and after the Court's decision in Alice.
The survey instructed the respondents that, unless otherwise
indicated, all questions related only to U.S. patents and only to financing
of activities in the United States. It did so because the focus of this
research is whether the Supreme Court's decisions have made an impact

111

United

States

Venture

Capital and Private

https://massinvestor.3dcartstores.com/UnitedStates

Equity

Database,

MASSINVESTOR,

[https://perma.cc/E3BK-F3U3].

1

Id.
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The sampling and incentives likely introduced selection effects that I consider later in this

Article. See infra Section V.D.

2020]

PA TENT ELIGIBILITY AND INVESTMENT

2045

on investment decisions, and the Supreme Court's decisions of course
relate only to U.S. law.
I conducted the survey primarily electronically using email. I
prepared the survey using Qualtrics software. Conducting the survey in

this way allowed me to use embedded logic that caused some questions
to appear or not appear depending on answers to earlier questions.114 To
distribute the survey, I sent an email with a short, unbiased description of
the project with a link to a website that hosted the survey. 115 Respondents
input their answers primarily using radio buttons. Research assistants
conducting the survey by telephone utilized a script that repeated the
language used in the electronic version of the survey.
I conducted the survey in the summer of 2017.
c.

What

While the survey includes too many questions to describe in detail
here, some overall comments on the content of the survey may prove
useful. I began the survey by asking basic introductory questions related

114

Thus, the survey did not present every respondent every question.

115

The description of the survey stated:
Recent U.S. Supreme Court decisions have changed the law of 'patent eligibility.' They
have made patents unavailable for certain things (like isolated human genes), and they
have made it more difficult to obtain patents for other things (like medical diagnostics
and computer software). This survey explores how these changes in the law of patent
eligibility impact investment decisions. (For more detailed information on the law
governing patent eligibility, you may click here www.uspto.gov/web/offices/pac/mpep/

s2106.html [https://perma.cc/LMB5-VFP7].)
This survey will ask questions about your firm's investment decisionmaking. Data
received through this survey will be held in confidence in an online database accessible
only with a login and password, and reported only in the aggregate, without identifying
individual respondents or their firms. It should take you between 5 and 12 minutes to
compete.
Those who complete the survey will later receive a report of the results. The results will
also serve as an important data point as various groups lobby Congress to amend the
patent statute to address the appropriate scope of patent eligibility.
Please note that, unless otherwise indicated, all questions relate only to U.S. patents and
only to financing of activities in the United States.
This survey is a research project of Prof. David Taylor at the SMU Dedman School of
Law, who may be contacted at dotaylor@smu.edu. Your participation is voluntary; you
may discontinue participation at any time without penalty. Clicking below indicates you
have read this disclosure and agree to participate.
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to whether patents encourage or discourage investment in efforts to
develop technology. After these initial questions, I asked questions
related to the effect of the ability of inventors to obtain patents on the
behavior of the respondent's firm. In particular, I asked questions
regarding whether the ability of inventors to obtain patents affects firm
decisions whether to invest in particular industries.
A common theme of my questions, starting with these, was to ask
separate questions for various industries. These industries include
computer and other electronics; semiconductor; pharmaceutical; medical
devices, methods, and other medical; biotechnology; communications;
transportation (including automotive); construction; energy; and
other.116 I ultimately asked whether the ability of inventors to obtain
patents in a particular industry affected their firms' decisions whether to
invest in companies developing technology in that industry, and, if so, to
what extent that decisionmaking is affected.

My next questions depended on whether the survey respondent
knew one or more of the Supreme Court's recent cases on patent
eligibility. If the respondent indicated familiarity with at least one of these
cases, I proceeded to ask a series of questions related to the effect of these

decisions on investment behavior. If a respondent indicated any of the
Court's decisions affected firm decisions on how to invest, I then asked a
series of follow-up questions. I concluded this section of the survey by
asking an open-ended question soliciting examples of how the Supreme
Court's decisions have affected firm decisions on how to engage in
financing.
Those respondents who indicated a lack of familiarity with any of
the Supreme Court's eligibility cases were asked a different set of
questions. While the previous section explored the respondent's view as
to how the Court's cases impacted their firms' investment decisions, in
this section I asked questions eliciting information that attempted to
answer the same questions when the respondent was not familiar with
any of the Court's cases. In particular, I asked about how their firms'
investment decisions have changed over the relevant time frame and
whether any such changes (or indeed lack of change) reflected reduced
availability of patents.

116

I derived these categories of industries from those used by the authors of Our Divided Patent

System, a recent article describing an empirical study. See generally John R. Allison et al., Our

Divided Patent System, 82 U. CHI. L. REv. 2073 (2015).
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In this discussion of the survey I have paraphrased the questions
actually used in the survey. To review particular questions, their order,
and their actual formulations, I have attached the entire survey as
Appendix A to this Article.
III.

DEMOGRAPHICS

In this Part, I provide data regarding the demographics of the survey
respondents. I also compare the demographics of the survey respondents
and non-respondents. I have attached all of the tables summarizing the

data generated by the survey as Appendix B to this Article.
A.

Respondent Demographics

A grand total of 475 investors participated in the survey.117 These
475 investors represented at least 422 separate investment firms.118 Of this
total, 461 participated online and 14 participated on telephone calls with
research assistants. Certain demographic information is known about the

respondents based upon the purchased database and additional data
received through the survey.

117

Not every respondent answered every question on the survey, in part due to embedded logic

in the survey, and as well because not every respondent completed every part of the survey. I note
below the number of respondents to particular questions.
118 The particular investment firm is not known for three of the 475 respondents.
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Investment Stage

The purchased database associated certain information with each
investor. This information, for example, identified the stage or stages of
investment on which each investor's firm focused. Thus, it is possible to
identify the proportion of the respondents whose firms focus on different
stages of investment.

Table 1: Investment Stages of Respondents' Firms
Stage
Early Stage
Seed Stage
Middle Stage
Growth Stage
Expansion Stage
Late Stage

Percent
59%
450%
27%
22%o
15%
1%

Notably, the majority of the respondents, 59%, were early stage
investors, and a full 45% were seed stage investors. The proportion of
middle, growth, expansion, and late stage investors gradually declined
from 27% down to 1%. The total of the percentages exceeds 100% because
the data identified multiple investment stages for most firms.
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Investment Industries

The respondents' firms invest in various industries. The industry in
which the highest percentage of the respondents' firms invest was
software and the Internet; a full 70% of the respondents report that their
firms invest in this industry. By contrast, the industry in which the lowest
percentage of the respondents' firms invest was construction at a stillhealthy 42%. Investments in the remaining industries hovered between

63% (medical devices) and 47% (transportation).
Table 2: Investment Industries of Respondents' Firms
Industry
Software and the Internet
Medical Devices
Computer Electronics/Hardware

Biotechnology
Pharmaceutical
Communications
Energy
Semiconductors
Transportation
Construction

Percent
70 o
63%
61%
55%
54%

53%
49%
48%
47%
42%

Note that more than half of the respondents reported their firms
invest in the software and Internet, medical devices, computer electronics
and hardware, biotechnology, pharmaceutical, and communications
industries. Only energy,
semiconductors,
transportation, and
construction fell below 50%. Again, the total of the percentages exceeds
100% because the data identified multiple investment industries for most
firms.
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The purchased database also identified the focus of the investments
of each of the respondent's individual firms. The focus of more than half
of the firms was information technology at 62%. The next closest foci
included life sciences and health care at 46%, as well as software and the
Internet at 40%. Every other focus garnered no more than 25% of the
respondents' firms. Notably, just 15% of the respondents' firms focused

on investments in medical devices. Note that the purchased data did not
identify pharmaceuticals or biotechnology as separate categories for a
firm focus.
Table 3: Investment Focus of Respondents' Firms

Finn Focus
Information Technology

Percent
62%

Life Sciences & Healthcare
Software & the Internet

46%
40%

Manufacturing & Industrial

25o

Business Services

23%

Communications & Networking
Energy & Clean Tech
Media & Digital Media

20%
19%
17%

Consumer Products & Services

16%

Financial Services
Medical Devices

15%
15%

Transportation & Distribution
Retail & Restaurant
Food & Agriculture

10%
9%
5%

Real Estate & Construction

5%

Semiconductors
Sports & Entertainment
Education & Training
Defense & Homeland Security
Storage & Hardware

4%
4%
3%
3%
3%

Electronics & Advanced Materials

2%

Again, the total of the percentages exceeds 100% because the data
identified multiple foci for most firms.
For multiple reasons, in the remainder of my analysis of the survey
results I utilize the respondents' identification of industries in which their
firms invest, rather than the purchased database's identification of
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investment firm focus. I do so because the survey itself requested this
information, providing more accuracy on this point, and because the

purchased database did not distinguish between the biotechnology and
pharmaceutical industries.119
3.

Familiarity with at Least One Eligibility Case

One of the questions in the survey asked if the respondent was
familiar with one or more of the four recent Supreme Court eligibility
decisions. The response to this question indicated whether the
respondent was relatively knowledgeable about patent eligibility, an
indication of what may be thought of as patent eligibility expertise. In
total, 38% of the respondents indicated they were familiar with at least
one of these cases.

Table 4: Familiarity with at Least One Eligibility Case
Type

Percent

Familiar

38%8

Unfamiliar

62%

B.

Comparison with Non-Respondent Demographics

The survey was sent to 14,641 investors and 3,304 investment firms
in total. Given participation by 475 investors representing at least 422
investment firms, the firm response rate was at least 12.78% and the
individual response rate was 3.24%.120
Notably, the demographics of the respondents differed somewhat
from the demographics of the non-respondents. In terms of investment
stage, a greater portion of the respondents were seed and early stage

119

That said, use of the respondents' identification of industries did not allow me to compare

the respondents and non-respondents' industry, and so below I use investment firm focus to make
this comparison. See infra Section III.B.
120

While low, these response rates do not differ substantially from the most similar, recent

survey. See Graham, supra note 97, at 1272 (reporting an 8.7% response rate).
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investors as compared to the non-respondents. A smaller portion of the

respondents were expansion, middle, and late stage investors.
Table 5: Investment Stages of Firms: Resp's v. Non-Resp's

Stage
Early Stage
Seed Stage

Middle Stage
Growth Stage
Expansion Stage
Late Stage

Resp's
59%
45%
27%
22%
15%

Non-Resp's

1%

3%

4900
30%

46%

22%
20%

Likewise, in terms of investment firm focus, the respondents' firms
differed somewhat from the non-respondents' firms.

Table 6: Investment Focus of Firms: Resp's v. Non-Resp's
Firm Focus
Information Technology
Life Sciences & Healthcare
Software & the Internet

Manufacturing & Industrial
Business Services
Communications & Networking
Energy & Clean Tech
Media & Digital Media
Consumer Products & Services
Financial Services
Medical Device
Transportation & Distribution
Retail & Restaurant
Food & Agriculture
Real Estate & Construction
Semiconductors
Sports & Entertainment
Education & Training
Defense & Homeland Security
Storage & Hardware
Electronics & Advanced Materials

Resp's
62%
46%
40%
25%
23%
20%
19%
17%
16%
15%
15%
10%
9%
5%
5%
4%
4%
3%
3%
3%
2%

Non-Resp's
55%
43%
32%
32%
33%
22%
23%
21%
24%
16%
13%
14%
11%
4%
6%

4%
5%
6%
5%
3%
1%
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Areas of more significant overrepresentation included information
technology and software and the Internet. Areas of more significant

underrepresentation included manufacturing and industrial, business
services, and consumer products and services.121
IV.

ANALYSIS OF SURVEY RESULTS

The survey has provided important data regarding the impact of the
Supreme Court's eligibility decision on investor decisionmaking. Overall,
this data helps to start answering the questions framed above: Whether
the Court's alteration of the law governing patent eligibility has impacted
decisionmaking with respect to investment; whether any impact has been
significant; and whether any impact has been negative in the sense of
reducing investment. In short, the results show that patent eligibility is an

important factor in investment decisionmaking, and that reduced
eligibility has had negative impact in every industry, but particularly in
the biotechnology, medical device, and pharmaceutical industries, and
particularly among those investors familiar with the recent cases
changing the law governing patent eligibility. In this Part, I present the

data generated by the survey and describe relevant conclusions to draw
from that data, all organized around four principal findings. Again, I have
attached all of the tables summarizing the data generated by the survey as
Appendix B to this Article.
A.

First Finding:Patent EligibilityIs an Important Considerationfor
Investors

The first principal finding is that patent eligibility is an important
consideration for investors. Investors who responded to the survey
overwhelmingly indicated patent eligibility is an important consideration
when their firms decide whether to invest in companies developing
technology.

im

For both over- and underrepresentation, here I identify areas of focus with a greater than 4%

difference in percentage of respondents versus non-respondents.
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Patent Eligibility Is Important

Overwhelmingly, investors reported that patent eligibility is an
important consideration when their firms decide whether to invest in
companies developing technology. About 43% of the respondents
strongly agreed that patent eligibility is an important consideration when
their firms decide whether to invest in companies developing technology.
Another 31% somewhat agreed with the same proposition. About 5%
strongly disagreed, while about 9% somewhat disagreed. In total, 74%
agreed while only 13% disagreed. 122
Table 7:

Patent Eligibility Is an Important Consideration in Fin
Decisions Whether to Invest in Companies Developing

Technology
Response

Percent

Strongy agree
Somewhat agree

43%

Neither agree nor disagree
Somewhat disagree
Strongly disagree

31%0
13%
9%
5%

The recognition that patent eligibility is an important factor when
investment firms decide whether to invest in companies developing
technology begs follow-up questions, such as whether increased eligibility
correlates to increased investment in these companies and whether

decreased eligibility

correlates to decreased investment

in these

companies. I asked two of these types of questions. The overall result is
that investors reported that reduced patent eligibility for a technology
makes it less likely that their firm will invest in companies developing that
technology.
The survey first asked if the law of patent eligibility makes patents
unavailable for a technology, whether their firms are less likely to invest
in companies developing that technology. About 23% of the investors
strongly agreed and 39% somewhat agreed, while about 7% strongly

disagreed and 13% somewhat disagreed. Thus, in total, 62% agreed that

12

There were 432 individual responses to this question.
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their firms are less likely to invest given the unavailability of patents, while

only 20% disagreed. 123
Table 8:

Less Likely to Invest if Patent Eligibility Makes Patents

Unavailable
Response

Percent

Strongly agree

23%

Somewhat agree

39%

Neither agree nor disagree

19%A

Somewhat disagree
Strongly disagree

13%
7%

The survey next asked if the law of patent eligibility makes patents
more difficult to obtain for a technology, whether their firms are less
likely to invest in companies developing that technology. About 19% of
the investors strongly agreed and 40% somewhat agreed, while about 5%

strongly disagreed and 17% somewhat disagreed. In total, 59% agreed
that their firms are less likely to invest given more difficulty obtaining
patents, while only 22% disagreed. 124
Table 9:

Less Likely to Invest if Patent Eligibility Makes Patents
More Difficult to Obtain

Response
Strongly agree

Percent
19%

Somewhat agree
Neither agree nor disagree
Somewhat disagree

40%
18%
17%

Strongly disagree

5%

These results, while perhaps not surprising, nonetheless confirm one
of the central premises upon which the patent system rests: the idea that
patents help spur investment in development of technology. 125 Moreover,

123

There were 426 individual responses to this question.

124

There were 421 individual responses to this question.

125

As discussed below, this and other "[s]urveys reveal that patents contribute to incentives to

invest, most acutely in the bio-pharmaceutical and medical device fields but elsewhere to varying
degrees as well." See generally Ohlhausen, supra note 67, at 149.
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the results tie this investment-spurring theory directly to patent eligibility
in particular.
a.

Important for All Stages of Investment

In this survey, early stage investors reported the highest average view
of the importance of patents, while late stage investors reported the lowest
average view of the importance of patents. There was no significant
difference, however, in views of whether patent eligibility is an important
consideration when firms decide whether to invest in companies
developing technology when taking into account the different stages of
investment upon which firms focused. 126 That is, there was no statistically
significant difference in responses as between firms that focus on seed,
early, middle, growth, expansion, and late stage investments. Most
notably, for all stages of investment, investors reported that patents are
important.
Table 10: Importance of Patent Eligibility by InvTestment Stage
Stage

Mean (1-5 Scale)

Seed
Early
Middle
Growth

3.95
3.98
3.95
3.84

Expansion
Late

3.88
3.80

Perhaps a larger sample size would indicate an actual trend. Patent
protection indeed may be most significant in the early stages of
entrepreneurial activity. 127 The earlier the stage of entrepreneurial activity
the greater the likelihood of technological development and invention,
and thus the more significant to investors that patents be available to

126

I used an analysis of variance test to compare the mean responses between stages of funding,

identifying means using numbers from 1 for "strongly disagree" to 5 for "strongly agree." I used a
significance level of 0.05.
127

See Mark A. Thompson & Francis W. Rushing, An Empirical Analysis of the Impact of Patent

Protection on Economic Growth: An Extension, 24

J.

ECON. DEV. 67, 68 (1999) (noting that

"protection [provided by] patents is the foundation for payoffs to entrepreneurs starting off the
chain of events that leads to economic expansion").
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protect those inventions. Later, after a technology has been developed or
at least mostly developed, the relevant entrepreneurial activities shift to
primarily non-inventive activities like manufacturing, marketing, and
distribution. Investors in these later stages of entrepreneurial activity
might focus less on the ability to patent prior inventions-it is likely any
patent applications should have already been filed-and instead on the
ability of the companies to capture market share quickly.128 These
investors still care about the eligibility of the underlying inventions, but
other considerations likely begin to dominate their investment
decisionmaking. That said, the point should not be overemphasized.
There was no statistically significant difference in this survey. Even
investors in later stages of entrepreneurial activity still ranked patent
eligibility as important. For example, late stage investors still rated patent
eligibility as important at 3.8 on a scale of 1-5.
b.

Important for All Industries

In this survey, investors investing in the medical device,
biotechnology, and pharmaceutical industries reported the highest
average view of the importance of patents. Those investing in software
and the Internet reported the lowest average view of the importance of
patents. As with stages of investment, however, there was no statistically
significant difference in views when taking into account different
industries.129 For example, there was no statistically significant difference
in responses as between firms that invest in biotechnology versus
software and the Internet. Again, most notably, for all industries,
investors reported that patents are important.

128

See Graham, supra note 97, at 1259 ("[B]ecause early-stage firms tend to lack the kinds of

complementary assets (such as well-defined marketing channels, manufacturing capabilities, and
access to cheap credit) that ease entry into the market, they are arguably even more sensitive to IP
rights than their more mature counterparts.").
129

I used an analysis of variance test to compare the mean responses between industries,

identifying means using numbers from 1 for "strongly disagree" to 5 for "strongly agree." I used a
significance level of 0.05.
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Table 11: Importance of Patent Eligibility by Industry
Industry

Mean (1-5 Scale)

Medical Devices
Biotechnology

4.17
4.13
4.13
4.07
4.04
4.01
3.99
3.99
3.98
3.92

Pharmaceutical
Energy
Semiconductors
Construction

Computer Electronics/Hardware
Transportation

Communications
Software and the Internet

Another way of understanding the data is to explore the percentage
of investors in each industry who agreed (either strongly or somewhat)
that patent eligibility is an important consideration in firm decisions
whether to invest in companies developing technology. This view of the
data reiterates the point that the great majority of investors in each
industry find patent eligibility to be an important factor in firm
investment decisionmaking, with the medical device, biotechnology, and
pharmaceutical industries at the top of the list in this survey. In short,
patents are important for every industry.
Table 12: Patent Eligibility Importance By Industry Percent
Strongly or Somewhat Agreeing Patent Eligibility Is an
Important Consideration in Firm Decisions Whether to
Invest in Companies Developing Technology
Industry

Percent

Medical Devices

81%

Biotechnology
Pharmaceutical
Energy

Semiconductors

79%
79%
78%
76%

Construction

76%

Computer Electronics/Hardware
Transportation
Communications
Software and the Internet

75%
75%
74%
72%

2020 ]

PATENT ELIGIBILITY AND INVESTMENT

2059

It would not be surprising to see a statistically significant difference
in the views of importance of patent eligibility between investors focusing
on the medical device, biotechnology, and pharmaceutical industries and
investors focusing on software and the Internet. It has long been the
predominate theory that patents are most necessary to spur inventive
efforts in the medical device, biotechnology, and pharmaceutical
industries given the significant costs involved in the development of
technologies in these industries and the ease of copying or reverse
engineering these technologies.13o Likewise, empirical evidence indicates
that patents play a particularly important role in creating incentives to
invest and innovate in the life sciences industries.131 Again, though, the
point should not be overemphasized. Beyond the lack of statistical
significance here, the survey indicates that, in the software and Internet
industry, 72% of investors rank patent eligibility as important to their
firms' investment decisionmaking.

130

See, e.g., Chetan Gulati, The "Tragedy of the Commons" in Plant Genetic Resources: The Need

for a New InternationalRegime Centered Around an InternationalBiotechnology Patent Office, 4
YALE HUM. RTS. &DEV. L.J. 63,73 (2001) (noting that "both [the pharmaceutical and biotechnology
industries] are particularly dependent on strong patent protection because of a combination of the
high costs of research and development that are necessary to produce new products and the relative
ease with which they can be copied via reverse engineering").
131

See Ohlhausen, supranote 67, at 125 ("Surveys reveal that patents contribute to incentives to

invest, most acutely in the bio-pharmaceutical and medical device fields but elsewhere to varying
degrees as well."); id. at 130 ("[E]mpirical evidence that patents drive innovation in pharmaceuticals
is especially strong... ." (citing Edwin Mansfield, R&D and Innovation: Some EmpiricalFindings,
in R&D, PATENTS, AND PRODUCTIVITY 127, 142-43 (1984))); Bronwyn H. Hall, Patents and Patent

Policy, 23 OXFORD REV. ECON. POL'Y 568, 574-75 (2007); Jean O. Lanjouw & lain M. Cockburn,
New Pillsfor Poor People? EmpiricalEvidence After GATT, 29 WORLD DEV. 265, 265, 287 (2001).
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Investors with Familiarity with the Supreme Court's Eligibility
c.
Cases Identify Eligibility as Important More Often than Investors
Without this Familiarity
Interestingly, there was a statistical difference when comparing the
responses of investors who reported familiarity with at least one of the
Supreme Court's recent eligibility decisions with the responses of
investors who did not report any such familiarity. Those with this
familiarity reported greater agreement that patent eligibility is an
important consideration when their firms decide whether to invest in
companies developing technology. 132 As discussed above, I refer to these
investors as, at least relatively speaking, eligibility knowledgeable
investors. In short, while eligibility knowledgeable investors and
eligibility unknowledgeable investors both report that patent eligibility is
an important consideration when their firms make decisions to invest in
companies developing technology, eligibility knowledgeable investors
place greater importance on patent eligibility.

Table 13: Importance of Patent Eligibility by Familiarity with at
Least One Eligibility Case
Type

Mean (1-5 Scale)

Familir
Unfaili jar

4.18
3.93

It may be that the more an investor knows about patent eligibility,
at least in terms of more knowledge regarding the Supreme Court's
eligibility cases, the more the investor believes patent eligibility is an
important consideration in the decision whether to invest in a company
developing technology. On the one hand, this correlation may indicate
that the more an investor learns about the Supreme Court's eligibility
cases, the more that knowledge (here, eligibility) impacts investment
decisions. That is, there may be a cause and effect relationship. On the
other hand, this correlation may simply reflect the idea that the more one

132

Here I used a 2 sample non-parametric Mann-Whitney U Test to compare the mean

responses between "experts" and "non-experts," using 1 for "strongly disagree" to 5 for "strongly
agree" to identify means. I used a significance level of 0.05.
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knows about a subject, the more importance that person places on his or
her own knowledge of the subject. 133
2.

Patent Eligibility Is Not Most Important

The availability of patents given eligibility, however, was not the
most important consideration to the investors. The survey asked
respondents to rank eight factors (and an "other" category left blank so
that they could input a factor) to identify the most important factors their
firms rely upon when deciding whether to invest in companies
developing technology.134 However one considers the responses, the
quality of a target company's people ranked as most important, followed
by the quality of the company's technology, followed by the size of the
potential market for the technology. The relative importance of the
remainder of the considerations depends upon how one organizes the
responses.

One way to understand the data is to consider the percentage of
respondents who ranked each consideration as first, second, third, fourth,
or fifth in importance. This method of organizing the data shows that
first-mover advantage received slightly more fourth place rankings as
compared to the availability of U.S. patent protection given U.S. patent
eligibility. Interestingly, however, the availability of U.S. patent
protection received many more fifth place rankings as compared to first-

mover advantage.

133

See Laura G. Pedraza-Farina, Understandingthe Federal Circuit: An Expert Community

Approach, 30 BERKELEY TECH. L.J. 89 (2015) (describing the tendency of expert communities to
emphasize the importance of their own expertise).
134

There were 395 individual responses to this question.
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Relied upon when Deciding to Invest in

Companies Developing Technology: Ranking (1-5 of 9)
Factor

Quality of People
Quality of Technology
Size of Potential Market
First-Mover Advantage

1st
48%
24%
19%

2nd
23%
31%
33%

3rd
14%
30%
26%

2%

13%

Avail. of U.S. Patents

2%

5%
4%

Avail. of Trade Secrets
Avail. of Foreign Patents

0%

1%

Avail. of Copyrights
Other

0%
0%
4%

1%

0%
3%

10%
2%
2%
1%
3%

4th
5%

5th
3%

10%

3%

12%
29%
27%
5%
5%
4%
4%

3%
14%
34%
17%
17%
7%
2%

Another way to understand the data is to calculate a weighted
average, giving the most important consideration nine points on down to
one point for the least important consideration. This method of
organizing the data shows that the availability of U.S. patent protection
given U.S. patent eligibility ranks as more important than first-mover
advantage. This method also causes the availability of foreign patents to
appear more important than the availability of trade secrets. Copyright
protection is the least important listed consideration in either manner of
organizing the data.
Table 15: Factors Relied upon when Deciding to Invest in
Companies Developing Technology: Weighted Mean
Factor

Mean (1-9 Scale)

Quality of People
Quality of Technology
Size of Potential Market
Avail. of U.S. Patents
First-Mover Advantage

7.77
7.55
7.24
5.31
4.94
3.72
3.31
3.13
2.03

Avail. of Foreign Patents

Avail. of Trade Secrets
Avail, of Copyrights
Other
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It is significant to recognize that the present survey focused on the
availability of patents based on patent eligibility, and that investors
ranked the availability of patents ahead of first-mover advantage and the
availability of other forms of intellectual property. These results were not
exactly consistent with other studies. A survey of start-up companies, for
example, indicated that start-up companies view patents as valuable, but
that start-up companies ranked patent availability slightly behind firstmover advantage in importance as an appropriability strategy. 1 3 5 I discuss
this other survey, and how the present survey compares to that survey, in

more detail below. 136
Sorting this data by the industries in which the respondents' firms
invest reveals that for every industry the availability of patents is less
important than the quality of the people, the quality of the technology,
and the size of the potential market. But for every industry the availability
of patents exceeds the importance of first-mover advantage and the
availability of foreign patents, trade secrets, and copyrights. Indeed, for

all but one industry-the semiconductor industry-the

order of

importance of all of the factors did not vary. In the semiconductor
industry, trade secrets and copyrights switched places in the order of
importance; the availability of copyrights exceeded the availability of

trade secrets in importance.
That said, investors did place different importance on the availability
of patents by industry. Respondents whose firms invest in the medical
device, pharmaceutical, and biotechnology industries placed the most
importance (among investors in any industry) on the availability of U.S.
patents. Respondents whose firms invest in the software and Internet
industry placed the least importance (again among investors in any
industry) on the availability of U.S. patents.

135
136

Graham, supra note 97, at 1289.
See infra Section V.A.
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Table 16: Importance of Availability of U.S. Patents when
Deciding to Invest in Companies
Developing
Technology: Weighted Mean (By Industry)

Industry

Mean (1-9 Scale)

Medical Devices
Pharmaceutical
Biotechnology
Energy
Other
Semiconductors
Construction
Transportation

5.42
5.42
5.41
5.36
5.35
5.31
5.31
5.26
5.26
5.24
5.18

Communications
Compiuters
Software and the Internet

The difference among industries comports to some degree with the
prior survey of start-up companies, which similarly revealed differing
views between the life science and software industries.137 Again, I
compare the survey results in more detail below. 138
This last recognition-that views among investors differ based upon
the industries in which their firms invest-previews the second principal
finding, which correlates reduced patent eligibility with particular

reported investment behaviors in particular industries.
B. Second Finding:Reduced PatentEligibility Correlateswith
ParticularReported Investment Behaviors in ParticularIndustries
The second principal finding is that reduced patent eligibility
correlates with particular reported investment behaviors in particular

industries. According to the investors, on average each industry would
see reduced investment, but the elimination of patents or a reduction in
patent eligibility would have a more devastating impact on the level of
funding in technological development in the pharmaceutical,

biotechnology, and medical device industries.

137

Graham, supra note 97, at 1292.

138

See infra Section V.A.
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1. On Average Investors Report the Elimination of Patent Protection
Would Cause Investment Firms to Reduce Investment in Every Industry
Investors as a whole indicated that, for each industry in which the
surveyed firms invest, the elimination of patents would cause the firms to
decrease their investments in companies developing technologies in

those industries. In other words, in every industry of the surveyed
investment firms, the elimination of patents would cause the firms on
average to decrease their investments.139 This is shown by calculating a
weighted average of responses to a question on point, giving the response
"significantly increase investments" five points on down to one point for
"significantly decrease investments." The weighted average for each
industry is less than three, indicating that on average investors report that
their firms would decrease investments in companies developing
technologies in an industry in view of the elimination of patents in that

industry.
Table 17: Impact

of Elimination of Patents on Investment

Decisions: Weighted Mean
Industry
Construction
Software and the Internet
Transportation
Communications

Energy
Computer/Electronic Hardware
Semiconductors
Medical Devices

Biotechnology
Pharmaceutical

139

Mean (1-5 Scale)
2.82
2.74
2.67
2.61
2.50
2.39
2.23
1.89
1.83
1.80

There were 330 individual responses to this question.
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More Investors Report Decreased Investment Caused by the
Elimination of Patents in the Life Sciences Industries

For particular industries, however, the decrease in investments

reported by investors as caused by the elimination of patents would be
more pronounced. As shown using the weighted averages, the three
industries with the least reported decrease in investments would be the

construction, software and the Internet, and transportation industries.
The three industries with the most reported decrease in investments
would be the pharmaceutical, biotechnology, and medical device

industries.
Another way to understand the data relating to the elimination of
patents is to consider for each industry the percentage of respondents
who indicated their firms would strongly increase investment, somewhat
increase investment, experience no impact, somewhat decrease
investment, and strongly decrease investment in view of the elimination
of patents in an industry.
Table 18: Impact of Elimination
Decisions: Responses

Industry

of Patents

on Investment

Strongly Somewhat No Somewhat Strongly
Increase Increase Impact Decrease Decrease

Construction
Soft. & the Internet

1%
3%

5%
10%

75%

14%
27%

6%

53%

Transportation
Communications

2%
2%

7%o

53%
48%

31%
32%

7%

8%

Energy
Comp. Elecs. Hard.

2%
4%

40%
6%

49%
33%

30%
39%

15%
18%

Semiconductors

4%

3o

33%

34%

27%

Medical Devices
Biotechnology

6%
7%

3%

2%

11%
14%

32%
22%

47%
55%

Pharmaceutical

7%

1%

19%

11%

62%

8%
10%

Considering the data in this way makes a few additional points clear.
Investors overwhelmingly indicated, for example, that the elimination of
patents would either not impact their firms' decisions whether to invest
in companies or only slightly decrease investments in companies
developing technology in the construction, software and Internet,
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transportation, energy, and computer and electronic hardware industries.
But investors, by contrast, overwhelmingly indicated that the elimination
of patents would either somewhat decrease or strongly decrease their
firms' investments in the pharmaceutical, biotechnology, and medical
device industries. Thus, according to these investors, on average each
industry would see reduced investment as a result of the elimination of
patents, but the extent of the impact on particular industries would be
different. The industries most negatively impacted would be the
pharmaceutical, biotechnology, and medical device industries.
3.

On Average Investors Report that the Decreased Availability of
Patent Protection Would Cause Investment Firms to Reduce
Investment in Every Industry

Investors as a whole indicated that, for each industry in which the
surveyed firms invest, the decreased availability of patents would cause
the firms to decrease their investments in companies developing
technologies in those industries.14o In other words, in every industry of
the surveyed investment firms, the decreased availability of patents would
cause the firms on average to decrease their investments. This is shown
by calculating a weighted average of responses to a question on point,
giving the response "significantly increase investments" five points on
down to one point for "significantly decrease investments." The weighted
average for each industry is less than three, indicating that on average
investors report that their firms would decrease investments in
companies developing technologies in an industry in view of the
decreased availability of patents in that industry.

14o

There were 307 individual responses to this question.
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Table 19: Impact of Decreased Availability of Patents
Investment Decisions: Weighted Mean
Industry
Construction
Transportation
Software and the Internet
Communications

Energy
Computer/Electronic Hardware
Semiconductors
Medical Devices

Biotechnology
Pharmaceutical

4.

on

Mean (1-5 Scale)

2.78
2.62

2.59
2.54
2.47
2.26
2.09
1.83

1.78
1.70

More Investors Report Decreased Investment Caused by the

Decreased Availability of Patents in the Life Sciences Industries
For particular industries, however, the decrease in investments

reported by investors as caused by the decreased availability of patents
would be more pronounced. As shown using the weighted averages, the
three industries with the least reported decrease in investments would be
the construction, transportation, and software and the Internet
industries. The three industries with the most reported decrease in
investments would be the pharmaceutical, biotechnology, and medical

device industries.
Another way to understand the data relating to the decreased
availability of patents is to consider for each industry the percentage of
respondents who indicated their firms would strongly increase
investment, somewhat increase investment, experience no impact,

somewhat decrease investment, and strongly decrease investment in view
of the decreased availability of patents in an industry.
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Investment Decisions: Responses

of
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Patents on

Strongly Somewhat No Somewhat Strongly
Industry
Increase Increase Impact Decrease Decrease
1%
3%
710
21%
3%
Construction
Transportation
2%
5%
540
32%0
7" a
Soft. & the Internet
1%
6%
53%
30%
9%
Communications
1%
5%
52%
31%
11%
Energy
2%
4%
48%
33%
13%

CompiElecs. Hard.

2%

4%

33%

40%

21%

Semiconductors
Medical Devices

1%
1%

2%
3%

30%
14%

40%
40%

27%
42%

Biotechnology

3%

2%

17%

29%

50%

Pharmaceutical

3%

1%

14%

25%

56%

Considering the data in this way makes a few additional points clear.
Investors overwhelmingly indicated, for example, that the decreased
availability of patents would either not impact their firms' decisions
whether to invest in companies or only slightly decrease investments in
companies developing technology in the construction, transportation,

software and Internet, energy, and computer and electronic hardware
industries. But investors, by contrast, overwhelmingly indicated that the
decreased availability of patents would either somewhat decrease or
strongly decrease their firms' investments in the pharmaceutical,

biotechnology, and medical device industries. Thus, according to these
investors, on average each industry would see reduced investment as a
result of the decreased availability of patents, but the extent of the impact
on particular industries would be different. Again, the industries most
negatively impacted would be the pharmaceutical, biotechnology, and

medical device industries.
C.

Third Finding: The Supreme Court's Eligibility Decisions Have
Impacted Firm Investment Behaviors

The third principal finding is that the Supreme Court's eligibility
cases have impacted many firms' existing investments and, more
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significantly going forward, firms' investment behaviors. A substantial
portion of investors familiar with the Supreme Court's eligibility
decisions reported that those cases have impacted their firms' investment
decisions, primarily in the sense of decreasing investments or shifting

investments between industries. They report the industries most
negatively impacted include the pharmaceutical, medical device, and
biotechnology industries.
1.

The Supreme Court's Eligibility Cases Negatively Impacted Firm's
Existing Investments

To understand investors' views of the impact of the Supreme Court's
eligibility cases, the survey first requested investors to identify whether
they were familiar with at least one of the four recent cases. More than
one third, 38% to be exact, indicated they were familiar with at least one
of the cases. 141 The survey then asked several follow-up questions to those
respondents who were familiar with at least one of the cases.
About 40% of knowledgeable investors indicated that the Court's
decisions had somewhat negative or very negative effects on their firms'
existing investments, while only about 14% of these investors reported
somewhat positive or very positive effects. 142
Table 21: Impact of Supreme Cou r's Eligibility Cases on Existing
Investments

Response

Percent

Very positive
Somewhat positive

1%
13%

No Impact

46%

Somewhat negative
Very negative

330%

7%

141

There were 373 individual responses to this question.

142

There were 138 individual responses to this question.
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The impact on existing investments, however, reflects only the static
impact of the Supreme Court's eligibility cases. What is more important
is the dynamic impact-in other words, the impact on investment
decisionmaking in the future, given the importance of the development
of technology, particularly in terms of the cumulative effects of
continuing improvements.
2.

The Supreme Court's Eligibility Cases Affected Firms'
Decisionmaking

On a going forward basis, one third of the investors who knew about
at least one of the Court's eligibility cases indicated that these cases
affected their firms' decisions whether to invest in companies developing
technology. Sixty-one percent, on the other hand, indicated that the cases
did not affect their firms' investment decisionmaking.143

Table 22: Have Any of the Supreme Court's Eligibility Cases
Affected Firm Decisions Whether to Invest in
Companies
Response

Percent

Yes
No
Don't know

33%
61%
6%

143

There were 135 individual responses to this question.
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Of investors at firms investing in the pharmaceutical, medical

device, semiconductor, and biotechnology industries, 37-39% indicated
the cases did affect their firms' investment decisionmaking. Of investors
at firms investing in software and the Internet, 32% indicated such
impact. Despite these numbers, there was no statistically significant
difference in these responses based on industry or stage of funding. 144

Table 23: Respondents Indicating the Supreme Court's Eligibility
Cases Have Affected Firm Decisions _Whether to Invest
in Companies, by Industry
Industries
Pharmaceutical
Medical Devices
Semiconductors

Percent
39%
38%
38%

Biotechnology

37%

Transportation
Communications
Computer Electronic Hardware
Construction

36%
35%G
34%
34%

Energy

33%

Software and the Internet

32%

The survey asked a series of follow-up questions to the investors who
indicated that the Supreme Court's eligibility cases had affected their
firms' decisions whether to invest in companies. In terms of which case
affected firm decisionmaking, investors most often identified Association
for MolecularPathology v. Myriad, while the case that received the least
votes was Bilski.145

144

In other words, investors consistently reported the Supreme Court's eligibility cases

primarily caused decreased investments, regardless of their investment firm's focus in terms of stage
of funding or industry. Here I used a chi-square test of multiple proportions to test the equality of
the proportion of respondents who answered "yes," broken down by stages of funding/industries.
I used a significance level of 0.05.
145

There were 85 individual responses to this question.
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Table 24: Which of the Supreme Court's Eligibility Cases Affected
Firm Decisions Whether to Invest in Companies
Response
Ass'n for Molecular Pathology v. Myriad
Mayo v. Prometheus
Alce v. CLS Bank
Bilski v. Kappos

Percent
33%
29%
20%
13%

This result-that the Supreme Court's decision in Myriad rated as
the most significant in terms of impacting investment firm decisions-is
somewhat surprising. It is arguably the narrowest of the four decisions,
given its focus on eligibility of DNA segments and cDNA,146 as opposed
to, more generally, business methods, medical procedures, or computer
software.147 By contrast, it is unsurprising that Bilski is ranked lowest
given that the Court did not make any major pronouncements in that
case. Instead, the Court merely indicated that the Federal Circuit's test for
eligibility was not the exclusive test and, in somewhat of a temporary
confirmation of expansive eligibility, held that business methods are not
categorically ineligible for patenting. 148 The most significant of the four
cases, at least in terms of changing the law of patent eligibility, probably

was Mayo Collaborative Services v. Prometheus Laboratories, Inc., a
decision derided by at least one commentator as "one of the worst
decisions in the patent space EVER!"149 Notably, Myriad and Mayo

address biotechnology and medical procedures, while Alice and Bilski
address computer-related technologies including software and business
methods. Thus, yet again, the survey results indicate that investors see the
Supreme Court's cases as more significantly impacting investment
decisions in the area of biotechnology as compared to software.

146

See generally Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013).

147

See generally Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014) (addressing computer

software); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012) (medical
procedures and in particular medical diagnostics); Bilski v. Kappos, 561 U.S. 593 (2010) (business
methods).
148
149

See generally Bilski, 561 U.S. 593.
Gene Quinn, Killing Industry: The Supreme Court Blows Mayo v. Prometheus, IP

WATCHDOG (Mar. 20, 2012), http://www.ipwatchdog.com/2012/03/20/supreme-court-mayo-vprometheus/id=22920 [https://perma.cc/66BW-2JNB].
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3. How the Supreme Court's Eligibility Cases Affected Firms'
Decisionmaking: Decreased Investments and Shifting of Investments
The relatively eligibility knowledgeable investors whose firm
decisionmaking was impacted by the Supreme Court's eligibility cases

reported these cases primarily caused decreased investments and shifting
of investments between industries.15o
Table 25: How Have the Cases You Selected Affected Firm
Decisions Whether to Invest in Companies
Percent
49%
34%
%

Response
Decreased investments overall
Shifted investments between industries
Increased investments overall
Other

9%

Notably, the percentage of these investors who reported increasing
investments as a result of the Supreme Court's known eligibility decisions

stood at 8%, significantly below the percentage indicating decreased
investments at 49%. There was no statistical significance, however, in
terms of any variations in answers based upon stage of funding or

industry.
4.

151

Shifting of Investments Away from Life Sciences Industries

As mentioned, one of investors' responses to the Supreme Court's
eligibility cases was to indicate shifting of investments from one industry
to another. Investors who shifted investments primarily identified
shifting investments out of the pharmaceutical, biotechnology, medical

device, and software and Internet industries. There was little indication
of shifting investments out of the communications or computer and
electronic hardware industries, and no indication of any shifting of

15o

There were 53 individual responses to this question.

is

Here, I used a chi-square test of multiple proportions to test the equality of the proportion

of respondents who answered "increased investments" or "decreased investments" or "shifted
investments," broken down by stages of funding/industries. I used a significance level of 0.05.
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transportation, energy,

or

Table 26: Investments Shifted Away from These Industries
Percent
2600

Industries
Pharmaceutical

Biotechnology

24%

Medical Devices

21%

Software and the Internet

21%

Communications

600

Computer/Electronic Hardware
Construction

3%/

Transportation
Energy

0%
0%

Semiconductors

0%

0%

Respondents identified shifting investments primarily into the

computer and electronic hardware, energy, medical device, and
software and Internet industries. To a lesser degree, investors
indicated they shifted

biotechnology,
industries. No

investments

into

the

pharmaceutical,

semiconductor, construction, and communications
one indicated their firm shifted investments into

transportation.153

152

There were 34 individual responses to this question.

153

There were 31 individual responses to this question.
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Table 27: Investments Shifted into These Industries
Industries

Percent

Computer/Electronic Hardware

16%

Energy
Medical De'ices
Software and the Internet
Pharmaceutical
Biotechnology

16%
13%
13%

Conunications

6%o
6%
6%
3%
3%

Transportation

0%

Semiconductors

Construction

One curious thing about this data is that some respondents
identified shifting investments into the same industries other
respondents identified shifting investments out of. The medical device
and software and Internet industries fall within this category. It is possible
what explains this anomaly is the importance of higher levels of
knowledge of eligibility law. Based on the data discussed below with
respect to the fourth principal finding (and given the holdings of the
relevant cases), it seems likely the less an investor knows about eligibility
law, the more likely that investor will report shifting investments into the

medical device and software and Internet industries. Conversely, it seems
likely the more an investor knows about eligibility law, the less likely that
investor will report shifting investments into the medical device and
software and Internet industries. This variance in eligibility law
knowledge (even within the category of investors familiar with at least
one of the Supreme Court's cases) may explain differences in responses.
Of course, what may also explain the difference is simple variability in

individual decisionmaking, in other words the randomness of individual
decisions. Furthermore, investors no doubt make investment decisions
based upon the particular bargain they are able to negotiate with target
companies; the decision whether to invest is not a fixed, binary decision
but dependent on the negotiated return on the investment, for example,
how much equity the investor may receive. Thus, the bargain or cost of
capital may get worse for the start-up company given the Supreme
Court's eligibility decisions, for example, but many investors assuredly
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still desire to invest at the lowest cost, or, in other words, for the
maximum return. And, all else being equal, the Supreme Court's
decisions may have reduced the cost to particular investors to such an
extent that they decide to invest more at least compared to the state of the
world prior to the Supreme Court's eligibility decisions.

D.

Fourth Finding: EligibilityKnowledgeable Investors Reported

Diferent Changes in Firm Investment as Compared to Non-Eligibility

KnowledgeableInvestors
The fourth principal finding is that investors familiar with at least
one of the Supreme Court's eligibility cases indicated different changes in
firm investment behavior as compared to investors without any such
familiarity.
1.

Most Investors Lack Familiarity with the Supreme Court's
Eligibility Cases

As a preliminary point, the survey shows that most investors
indicated they were unfamiliar with the four recent Supreme Court

eligibility cases. As discussed above, 62% indicated they were unfamiliar.
2.

Eligibility Knowledgeable Investors Reported More Impact as
Compared to Non-Eligibility Knowledgeable Investors

Moreover, as discussed above, about one third of investors familiar
with at least one of the Supreme Court's eligibility cases reported that
these cases impacted their firms' investment behavior, with 49% of these
investors reporting decreased investment and 34% reporting shifting of
investment between industries. Those investors who reported shifting of
investments indicated primarily that investments moved away from the
pharmaceutical, biotechnology, medical device, and software and
Internet industries.
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Investors unfamiliar with the Supreme Court's cases, by contrast,
overwhelmingly reported that the decreased availability of patents since
2009 (prior to the Supreme Court's eligibility cases) had not impacted
their firms' changes in investment behavior. 154 I asked this question in an
attempt, however imperfectly, to compare the responses of eligibility
knowledgeable investors and eligibility unknowledgeable investors with
respect to their belief in how changes in the law of patent eligibility
resulting in decreased availability of patents have impacted their firms'

investment behavior.
Table 28: Has Decreased Availability of Patents Since 2009
Contributed to Your Firm's Change in Investments

(Unknowledgeable Investors Only)
Type of Change
No Change
Inc'd investments overall
Dec'd investments overall
Shifted investments b/w industries

Yes

No

2%

95%

4%

0%
14%
4%

88%

12%
5%
12%

82/

84%

Don't Know

Given that these respondents were not familiar with any of the
Supreme Court's eligibility cases, it perhaps would not be surprising if

they had indicated they did not know whether any decreased availability
of patents had impacted their firms' investment behavior. Yet these
respondents overwhelmingly selected no impact rather than reporting
lack of knowledge of impact. By answering the question, they seem to
have indicated they were aware of decreased availability of patents, even
if they were not specifically familiar with the cause being the Court's
eligibility cases. Moreover, regardless of the cause of decreased
availability of patents, even these eligibility unknowledgeable
respondents reported more often decreasing investments as compared to
increasing investments as a result of the decreased availability of patents.

Indeed, none of these respondents indicated that decreased availability of
patents caused their firms to increase investments, while 14% reported

decreased availability of patents contributed to decreased investments.

154

There were 58 individual responses to this question from investors who indicated no change,

125 from investors who indicated increased investments, 22 from investors who indicated
decreased investments, and 49 from investors who indicated shifting of investments between
industries.
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3. Eligibility Knowledgeable Investors Reported Different Shifting of
Investments as Compared to Non-Eligibility Knowledgeable Investors
Investors without eligibility knowledge indicated more often, as
compared to investors with eligibility knowledge, that their firms have
shifted investments out of certain industries. While eligibility
knowledgeable investors most often reported shifting investments out of
the pharmaceutical industry, unknowledgeable investors reported
shifting investments out of energy and semiconductors, industries that
did not even make the list for knowledgeable investors. Also, notably,
eligibility knowledgeable investors reported three times as often shifting

investments out the software and Internet industry as compared to
unknowledgeable investors. Eligibility unknowledgeable investors also
more moderately reported shifting investments out of the biotechnology

and medical device industries as compared to knowledgeable investors. 155
Table 29: Eligibility
Unknowledgeable
Investors
Investments Away from These Industries
Industries
Energy
Semiconductors
Pharmaceutical
Medical Devices

Biotechnology
Communications
Computer/Electronic Hardware

Software and the Internet
Construction
Transportation

Shifted

Percent
17%
12%
11%
11%
10%
10%

10%
7%
3%
2%

155 There were 115 individual responses to this question from eligibility unknowledgeable

investors.
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In terms of industries into which investors shifted investments, there
were also differences
between eligibility knowledgeable
and
unknowledgeable investors. Investors without eligibility knowledge
indicated more often, as compared to investors with eligibility
knowledge, that their firms have shifted investments into the software
and Internet industry as compared to all other industries. While eligibility
unknowledgeable investors reported 32% of the time shifting of
investments into this industry, knowledgeable investors reported shifting
investments into software and the Internet merely 13% of the time.156

Table 30: Eligibility

Unknowledgeable

Investors

Shifted

Investments into These Industries
Industries
Software and the Internet
Computer/Electronic Hardware
Transportation

Percent
32%
11%
11%

Medical Devices

10%

Communications

8%

Biotechnology

5%
5%

Energy
Pharmaceutical
Constriction
Semiconductors

3%
3%
2%

In short, over the time period of the Supreme Court's eligibility
cases, eligibility knowledgeable investors reported more often reduced
investment in software and the Internet as compared to unknowledgeable
investors, who more often reported increased investment in software and
the Internet over the same time period.

156

There were 97 individual responses to this question from eligibility unknowledgeable

investors.
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Eligibility Knowledgeable Investors' Comments Were
Overwhelmingly Negative

The survey asked eligibility knowledgeable investors to describe
examples of how any of the Supreme Court's decisions on patent
eligibility in the seven years prior to the survey have affected their firms'
decisions on how to invest in companies.
To get a sense of the feelings of the eligibility knowledgeable
investors who provided comments, first, all of the descriptions were

coded as positive, negative, or other. Positive descriptions included
responses with positive characterizations of the impact of the Supreme
Court's cases as well as responses indicating increased investment.
Negative descriptions included responses with negative characterizations
of the impact of the Supreme Court's cases as well as responses indicating

decreased investment. Other descriptions included neither positive nor
negative characterizations, nor indications of changes in investments.
Remarkably, almost 83% of the comments fell into the negative category,
while only 13% fell into the positive category.

Table 31: Eligibility Knowledgeable
Positive or Negative

Investors'

Characterization

Percent

Positive
Negative
Other

13%'

Comments:

830/o

40o

Eligibility knowledgeable investors' descriptions were also coded by
industry. In total, these descriptions addressed only three industries. The
most common industry discussed by these investors was software and
Internet (35%), followed by biotechnology (30%), and the pharmaceutical
industry (13%). A significant portion of the descriptions was generalized
and not specific to any industry (35%).157

157

Some descriptions, however, addressed multiple industries, and so the grand total of these

portions exceeds 100%.
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Investors'

Comments:

Percent by Industry
Industries
Software and the Internet
Biotechnology

Percent
35%
30%

Phanmaceutical
Medical Devices
Semiconductors
Transportation
Comnumications
Computer/Electronic Hardware
Construction
Energy
Generalized

13%
0%
0%
0%
0%
0%
0%
0%
35%

Matching positive and negative comments with the industries

addressed by those comments provides the ability to get a sense of the
feelings of these eligibility knowledgeable investors who provided
descriptions of the impact of the Supreme Court's eligibility decisions.
Within the software and Internet industry, for example, eligibility
knowledgeable investors reported negative impact in 63% of the
comments and positive impact in 25% of the comments. Within the
biotechnology industry, eligibility knowledgeable investors reported
negative impact in 86% of the comments and positive impact in 14% of
the comments. And within the pharmaceutical industry, eligibility
knowledgeable investors reported negative impact in 100% of the
comments. Likewise, in the residual category, where the comments did
not address any particular industry, eligibility knowledgeable investors
reported negative impact in 100% of the comments.
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Table 33: Eligibility
Knowledgeable
Investors'
Percent Positive and Negative by Industry
Industries
Software and the Internet
Biotechnology
Pharmaceutical
Medical Devices
Semiconductors
Transportation
Comrnnications
Computer/Electronic Hardware
Construction

Energy
Generalized

Positive
25%
14%
0%
0%
0%
0%
00
0%
0%
00
0%
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Comments:

Negative
63%
86%
1000%
0%
0%
0%
0%
0%
0%
0%
1000%

What is perhaps even more interesting, however, is the substance of
the descriptions provided by eligibility knowledgeable investors when
asked about the impact of the Supreme Court's decisions. While there
were too many descriptions to discuss every one here, a few
representative examples will provide a glimpse into the prevailing
sentiments.
Regarding the software and Internet industry, representative
comments reflect the view that the Supreme Court's decisions have

reduced investment in software-based inventions and made softwarebased companies vulnerable to copycats. One eligibility knowledgeable
investor simply stated: "We no longer place any value or advocate for any
budget for software patents." Another investor lamented that "[p]atents

on computer-software based inventions are much harder to get now, but
software has been the engine of high tech for years. Lack of patent
protection makes companies more vulnerable." At least some investors,
however, indicated they have increased investments in the software field.
One, for example, tersely explained his or her firm "[i]nvested more after

Alice."
In the biotechnology and pharmaceutical industries, representative

comments reflect reduced investment in diagnostics, an increase in
uncertainty, and adverse impact on investments more generally. One
eligibility knowledgeable investor, for example, simply stated: "We have

CARDOZO LAW REVIEW

2084

[Vol. 41:2019

been far more cautious investing in diagnostics due to AMP v. Myriad."
Another provided a longer explanation and a prediction:
The specific decisions have increased [sic] uncertainty and the
treden [sic] is the most worrying because biotech, which will
drive 100 percent of the cures for disease that will save so many
lives and so much money compared to our ineffective healthcare
system, is 100 percent driven by patents. The potential patent
reforms and the direction of the courts will reduce investments
markedly if they keep going that direction.
Still another investor recognized the underlying premise of denying
patent eligibility on claims to naturally occurring phenomena, but still
complained about the result with respect to investment decisions: "In the
biotech/pharma area, the notion of naturally occurring phenomena being
harder to patent is easier to fathom, but it still makes a difference in terms
of availability of patent protection and the resulting adverse influence on

decisions to invest."
As already mentioned, some of the comments did not address
particular industries but instead provided generalized commentary on
the impact of the Supreme Court's eligibility decisions on the investment
market. As mentioned, all of these comments were negative. Here is a
sampling of those comments:
" "Caused us to defer investment till more clear milestones were

achieved to reduce risk. More due diligence to understand market
impact. Passed on several deals due to uncertainty of potential
litigation or market impact."
" "These SC decisions have dramatically impacted the secondary
market for patents. The secondary markets were once a useful
hedge when making seed stage investments to cutting edge
technology companies-if a company failed, at least you could
sell or license the IP to recover some or all of the invested funds.
That critical hedge is now missing. There is a hole in the
innovation ecosystem as a result of these disastrous SC

decisions."
" "They have impacted the value of licensing from universities and
company valuations based on patents that are affected by court

decisions."

PATENT ELIGIBILITY AND INVESTMENT

2020 ]

2085

Thus, these investors identified various problems caused by these
Supreme Court decisions on investments generally, not limited to
delayed or reduced investment. They, however, also explained why the
Court's decisions impacted investment, highlighting uncertainty,
potential litigation, market impact, elimination of the ability to hedge

investments, reduced value of licensing from universities, and reduced
company valuations.
V.

CLARION CALL TO FIx PATENT ELIGIBILITY LAW?

Proponents of reform may claim the results of the survey represent
a clarion call to fix patent eligibility law. Certainly, the results provide
data for an evidence-based evaluation of competing arguments in the
ongoing debate about the need for congressional intervention in the law
of patent eligibility. And the results do indicate reports of reduced
investment generally, and in particular in the biotechnology, medical
device, and pharmaceutical industries, as a result of the Supreme Court's
patent eligibility cases.
A.

Where the Results Fit Within the Existing Literature

The results of the survey supplement the results of other broader

studies and surveys. Together, these studies and surveys support the idea
that the availability of patents is an important factor in attracting venture
capital and private equity investment in businesses developing
technology in all industries, but particularly in the biotechnology,
medical device, and pharmaceutical industries. What the current survey
uniquely highlights, however, is the negative impact of the Supreme
Court's recent patent eligibility decisions on this investment. That is a

new finding, and one that deserves extended consideration.
Despite the number and breadth of the prior studies and surveys
discussed above-and their support for the idea that the patent system
promotes investment generally and in particular in the health sciences
industries-not one of them explores particular patent law doctrines that
might drive investment decisions.158 Indeed, in her own summary of this

158

See supra Section IC.
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literature, Commissioner Ohlhausen recognized that "the empirical

evidence to date remains incomplete about the precise circumstances in
which incremental strengthening of patent rights enhances or hurts
innovation." 159
Given the Supreme Court's recent upheaval in the law governing
patent eligibility and, moreover, the extreme reduction in patent
eligibility combined with the proliferation of calls to overturn the Court's
new test for patent eligibility, it seemed to me the perfect time to conduct
a survey to explore the impact of the Court's cases on investment in
technological development. Commissioner Ohlhausen, I suspect, would
agree. Beyond highlighting the lack of empirical evidence about the
impact of incremental strengthening or weakening of patent rights, her
analysis acknowledged both that the Supreme Court "has limited the
sphere of patentable subject matter"160 and, more generally, that "the
collective legal environment has been hostile to U.S. patent owners."161
She recognized, moreover, that problems critics associate with business
method and software patents in particular-ambiguity, patent thickets,
royalty stacking, modest disclosures, and issuance "without the benefit of
a rich prior art with which to make informed non-obviousness and

novelty decisions"-have been attributed "to the Federal Circuit's 1998
decision in State Street Bank [& Trust Co. v. Signature FinancialGroup,
Inc.]." 162
That case, as it turns out, addressed the legal doctrine of patent
eligibility; the court held that methods are eligible for patenting if they
achieve a "useful, concrete, and tangible result."163 According to
Commissioner Ohlhausen, the results of that decision included
"thousands of business method patents" issued "often without the benefit
of a rich prior art with which to make informed nonobviousness and
novelty decisions."164 In turn, those poor quality patents caused a

"disconnect between invention and commercialization" and "ha[ve]
Ohlhausen, supra note 67, at 150.
Id. at 107.
161 Id. at 108.
162 Id. at 113-14.
163 State St. Bank & Tr. Co. v. Signature Fin. Grp., Inc., 149 F.3d 1368, 1373 (Fed. Cir. 1998)
(quoting In re Alappat, 33 F.3d 1526, 1557 (Fed. Cir. 1994)), abrogatedby Bilski v. Kappos, 561 U.S.
593 (2010).
164 Ohlhausen, supra note 67, at 114.
159
160
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likely generated a perception-whether justified or not-that some
patents do not drive innovation and protect against copying, but simply
tax those who develop and market technologies."165 Thus, she has
acknowledged that many recent complaints regarding patent law focus
on business method and software patents, and that these complaints may
be tied back to the Federal Circuit's prior law governing patent eligibility.
Notably, the Supreme Court's recent patent eligibility cases
effectively replaced the test for eligibility set forth in State Street Bank, the
Federal Circuit case Commissioner Ohlhausen highlighted. No longer is
the test whether an invention achieved a "useful, concrete, and tangible
result," but instead whether the invention includes an "inventive
concept." 166 In this way, Commissioner Ohlhausen practically laid out the

case for the survey I conducted.
In addition, Commissioner Ohlhausen's conclusions-the result of
her study of the then-existing state of the econometric and survey
literature-may be tested against my new survey results. Her "view-in
light of the relevant theory, econometric evidence, and the U.S.
experience with a successful innovation policy of which patents form a
central part-is that strong patent rights should remain at the heart of the
U.S. industrial policy." 167 But "[t]hat does not mean uncritical embrace of

ever-broader patents in all industries."168
In short, my survey-the first of its kind-provides empirical survey
data unlike any existing study to the extent it focuses particularly on the
law of patent eligibility. This data is necessary to address the central
question of the Supreme Court's impact on investment in technological
development, to analyze the need to modify the current law governing
patent eligibility, and to determine whether any modification ought to
take into account differential impact on particular industries. And, as

shown above and summarized below, the data indicates the Court's cases
have impacted decisionmaking regarding investment in technological
development, there is a need to modify the current law governing patent
eligibility (at least if there is a desire to return to prior levels of investment
in technological development), and that any modification may take into
account differential impact on particular industries.

165

Id.

166 See supra Section L.A.
167
168

Ohlhausen, supra note 67, at 109.
Id.
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The Survey Highlights the Importance of Patent Eligibility and the
Negative Impact of the Supreme Court's Eligibility Cases

The results of the survey highlight the importance of patent
eligibility and the negative impact of the Supreme Court's eligibility cases
on venture capital and private equity investment in all industries, but
particularly in the most important areas of technological development in
terms of its impact on public health: the biotechnology, medical device,
and pharmaceutical industries. The results indicate to me at least that
Congress should at least consider overturning the Supreme Court to
prevent any more lost technological development in the United States.
The survey results indicate that investors as a whole believe patent
eligibility is an important consideration in deciding whether to invest in
a company developing technology.169 Furthermore, the results indicate
that a significant portion of the investors who are familiar with the
Supreme Court's cases believe these cases have reduced their firms'
investments in technological development in all industries.17o These
investors report primarily decreased investments, but also shifting of
investments between industries, and in particular out of life sciences
industries.17, That is not a good report if the goal is to maintain the same
level of investments, let alone increase investments, in the development
of technology, and in particular in the life sciences industries. And this
result is particularly remarkable given that the elimination or reduction
of patents would presumably reduce the risk of exposure to patent
litigation for companies in which these investors invest. Investors seem
to think the upside of patent eligibility is greater than its downside-that
is, that patent protection is worth more than the risk of patent
infringement lawsuits.
According to the survey results, moreover, the most significant
harm to investment in technological development has occurred in the life
sciences industries.172 Investors reported that the Supreme Court's
eligibility cases most severely impacted technological development in the
biotechnology, medical device, and pharmaceutical industries. While the
particular impact of delay and lost inventions in the life sciences

17U

See supra Section IV.A.
See supra Section IV.C.2.

171

See supra Sections IV.C.3, IV.C.4.

172

See supra Section IV.C.4.

169
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industries is unknown, if the reported decreased investment in, and
shifting of investment out of, the life sciences industries are true, it is
highly likely the Court's decisions have delayed or altogether prevented

the development of medicines and medical procedures.
On the other hand, most investors (62%) were not familiar with any
of the Supreme Court's eligibility cases, and even among investors with
familiarity most (61%) had not changed their investment decisionmaking
after these decisions. Only 38% of investors were familiar with any of the
Court's eligibility cases; only 33% of those familiar with at least one of
these cases reported that the case(s) impacted their investment
decisionmaking; and of the resulting small subset of investors, only 49%

reported decreased investments. In other words, only about 6% (38% x
33% x 49%) reported decreased investment resulting from the Supreme
Court's eligibility cases. And even that number must be offset by the
approximately 1% (38% x 33% x 8%) that reported increasing
investments as a result of these cases. Thus, one might argue, the survey
has shown only that, net, about 5% of investors report decreased
investment as a result of the Supreme Court's eligibility cases. And that,
so the argument goes, is slight. Moreover, the survey did not reveal the
size of changes in investments, individually or collectively, in terms of
dollars.
This simplified characterization of the data, however, fails to tell the
whole story. It is incomplete, for example, in its appreciation for the
impact of the Supreme Court's eligibility cases because it fails to consider
the shifting of investments between industries. Moreover, even 5% of
investors decreasing investment represents substantial impact on
investment in technological development. And perhaps the more
investors become familiar with the Supreme Court's eligibility cases, the
more their views will change to reflect the almost 50% of investors
familiar with at least one of the Supreme Court's cases who reported
decreased investments as a result of those cases-and so the relevant
portion of investors who decrease investments will only increase over
time. Still another problem is the dynamic impact of reduced investment,
here lost cumulative effects of continuing improvements, which is like
lost compound interest. Next, consider the differential impact between
industries, and in particular the life sciences industries where decreased
investment no doubt results in delay-and may also result in loss-of the
invention and marketing of medicines and medical procedures, even life-
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saving medicines and procedures. Furthermore, even among those
unfamiliar with the Supreme Court's cases, there were reports of negative
impact of patent eligibility on investments. In short, the survey paints a
problematic story of reduced investment in technological development in
the United States as a direct result of the Supreme Court's decisions.
C.

Limitations on Use of the Survey Data

That said, the data should be taken with a grain of salt. Surveys, for
example, reveal stated preferences, but not necessarily actual preferences.
I have already highlighted some of the ways to characterize the data to
support maintaining the status quo with respect to eligibility law.173
Moreover, I have pointed out that some of the questions received a small
number of responses.174 Additional reasons exist limiting the significance
of the survey results.
The views of the investors who responded to the survey may not
perfectly represent the views of all investors and investment firms.

Besides the limited sample size, Massinvestor's database may not be
representative. The views of individual investors, furthermore, may not
reflect the views of the investors' firms. The data set, moreover, reflects
that almost all of these investors' firms invest in multiple industries and
in multiple stages. This may explain why answers to some of the questions

did not exhibit statistically significant differences between industries and
between investment stages. Moreover, it is at least possible that the
description of the survey or the first part of the survey, which asked about
the importance of patent eligibility to investment decisions, impacted
responses to the second part of the survey, which asked more specific
questions about the impact of changes to patent eligibility law on

investment decisions. After reading the description and answering the
questions in the first part, respondents may have felt like patents were
more or less important than they actually were to these respondents prior
to reading the description and answering the questions in the first part of

173

See supra Section V.B.

174

See supra Section V.B. Given that some of the questions asked in the survey elicited few

respondents, the results may not be representative of the entire database of venture capital and
private equity investors, let alone these types of investors more generally.
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the survey. If so, the results of the second part of the survey could have
been biased in favor or against the importance of patents. 175The first part,
however, likely did not impact responses to questions asking about any
differences between technologies. Hindsight bias is another possibility
given that I asked questions about how investment decisions have
changed over a long time period. Respondents may have subconsciously
answered questions in a way that shows that they predicted the Supreme
Court's patent eligibility decisions even when they likely did not, for

example, by indicating that their investment decisions did not change as
a result of these decisions when in fact they did.

Selection bias is always a concern with any survey. Indeed, decisions
made while designing the survey necessarily impacted the survey results.
Selecting the 2017 version of the database, for example, introduced
selection bias in some ways. The collection of investors identified in this
database in 2017 no doubt differs from the collection of venture
capitalists that might have been identified in a similar database in 2009,
prior to the Supreme Court's four most recent eligibility cases. And this
difference may influence the outcome of the survey in various ways.
Suppose, for example, that at least some firms that engaged in venture
capital financing in 2009 decided to stop engaging in venture capital
financing after the Supreme Court's Mayo decision in 2013. In that

situation, the survey of firms identified in the database in 2017 does not
cover the entire data set of firms whose investment decisions changed
based on the Supreme Court's eligibility decisions. On the other hand,
suppose that some firms decided to begin venture capital financing in
2011 after the Supreme Court's Bilski decision. In that situation, the
survey of the firms identified in a 2009 database would similarly not
capture all of the firms whose investment decisions changed based on the

Supreme Court's eligibility decisions. I decided to use the 2017 version of
the database, and simply to recognize the imperfectness and inherent

175

Thus, there is at least a possibility of priming or demand effect. That said, I drafted the

description and the questions in an attempt not to cause priming or demand effect.

CARDOZO LAW REVIEW

2092

[Vol. 41:2019

selection effect.176 Unlike other surveys related to patent reform topics, 177
however, the survey here was not sent to an inherently biased sample, nor

did it indicate one way or the other whether the survey was intended to
provide data to support or defeat proposed legislation related to patent
eligibility. 178

In addition, the respondents may not have understood each
question or, for other reasons, not answered questions accurately. For
example, particularly for investors without knowledge of the Supreme
Court's eligibility cases, some investors may not have understood
eligibility as a distinct concept from patentability (which requires not just
eligibility but also novelty, non-obviousness, and compliance with the
disclosure requirements of the patent statute). As another example, it may
be difficult for some firms to differentiate between U.S. and foreign

activity. Investment decisions no doubt often present questions of
whether to invest in U.S. or foreign companies, or U.S. domestic
operations versus global operations. More significantly, respondents may
not really understand how the Supreme Court's patent eligibility cases
have actually impacted their firms' decisionmaking. And at least some

questions may have presented dichotomies dependent upon undefined
circumstances. For example, to answer the question whether a firm is less
likely to invest in companies developing technology if the law of patent
eligibility makes patents unavailable for that technology, some
respondents may have thought the answer depends upon the particular
technology at issue and whether trade secret protection would work to

176

I could have added questions to my survey to try to account for this selection bias. I could

have asked, for example, whether the surveyed entity was aware of firms that exited venture capital
financing in light of the Supreme Court's eligibility decisions. In light of the limited space and time
in my survey as well as the imprecise nature of the question, however, I did not include these types
of questions.
177

See, e.g., David L. Schwartz & Jay P. Kesan, Analyzing the Role of Non-PracticingEntities in

the Patent System, 99 CORNELL L. REV. 425, 434-36 (2014) (describing the probability of "strong
selection bias" in a survey conducted by a defensive patent aggregator).
178

Id. at 446 (indicating the survey in question was sent by a defensive patent aggregator to its

clients and prospective clients with "documentation inform[ing] potential subjects that the results
of the study would be used to lobby for changes in the patent laws"). Here, by contrast, the recipients
received an introduction stating that "[t]he results [of the survey] will ...

serve as an important data

point as various groups lobby Congress to amend the patent statute to address the appropriate
scope of patent eligibility," without taking a position on the question, without indicating the
personal views of the creator of the survey, and furthermore neutrally explaining that the "survey
explores how these changes in the law of patent eligibility impact investment decisions." See supra
note 115.
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protect any investment leading to its commercialization. Even given this
possibility, it seems likely that investors' answers simply reflect normal
circumstances they encounter.
Another limitation is that, even if the views of individual investors
reflect their firms' views and selection bias is not a significant problem,
different firms invest in different amounts. In other words, there are small
investments and large investments, and firms may be small investors or
large investors. It may be that large investors have different views
compared to small investors, and so the impact of the Supreme Court's
cases on investment as a whole may be different than the impact the
average investor reports.
The survey also does not really answer the question of whether
increased investment in technological development is a net benefit for
society. It is a basic premise of the patent system that patents incentivize
investment in technological development, and therefore the burden is no
doubt on opponents of the patent system to develop reliable data that the
patent system disserves technological development. At some point,

however, increasing investment in any industry becomes suboptimal
given opportunity costs. The survey does not attempt to answer the
question of whether more investment would advance social welfare given

associated costs.
Even recognizing these limitations, the survey does provide useful
data that can be used to begin analyzing the question of whether the
Supreme Court's eligibility cases have impacted investment
decisionmaking. The survey directly surveyed investors to explore
whether patent eligibility is a factor they consider when making their
decisions on investments in technological development and how their
decisionmaking has changed in view of and over the same time period as
the Court's cases. As discussed, despite limitations on the significance of
some of the results, the survey does provide evidence that these cases have
generally reduced investment in the development of technologies in all
industries, but particularly in the biotechnology, medical device, and
pharmaceutical industries. That advances the state of the literature
significantly, and in my view provides an additional reason for Congress
to consider whether the Court's cases ought to be overruled by statute.
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CONCLUSION

The survey I conducted was the first of its kind-one gathering data
that identifies changes in investment behavior and links those changes to
Supreme Court decisions in the area of patent eligibility. As a result, it has
provided critical data useful to evaluate empirically whether Congress

should amend the patent statute to end the Supreme Court's "drastic and
far-reaching experiment in patent eligibility standards."179 This data fills
major gaps left by prior studies generally linking patents and
innovation.180 Likewise, this data augments the overwhelming anecdotal
evidence of negative effects of the Court's heightened eligibility standard
on investment in technological development in the United States.181
Most importantly, the survey uniquely highlights one of the most
significant negative effects of the Supreme Court's recent patent eligibility

decisions: reduced venture capital and private equity investment in
technological
development generally, but particularly in the
biotechnology, medical device, and pharmaceutical industries. Future
work may be able to confirm these negative effects, for example by
exploring revealed preferences through actual investment behaviors of
venture capital and private equity investors. In the meantime, the major
takeaway is clear: The Supreme Court's "drastic and far-reaching
experiment in patent eligibility standards" has likely resulted in lost
investment in the life sciences that has delayed or altogether prevented

the development of medicines and medical procedures.

179

See Lefstin, supra note 2, at 554.

18U Ohlhausen, supra note 67, at 125 (describing "abundant empirical work finding that patent

strength and R&D expenditures are correlated;" "research show[ing] that strong IP rights are
associated with economic growth in developed economies;" and "[s]urveys reveal[ing] that patents
contribute to incentives to invest, most acutely in the bio-pharmaceutical and medical device fields
but elsewhere to varying degrees as well").
181 See, e.g., Thomas, supra note 3; U.S. PATENT

supra note 6, at 243.

& TRADEMARK OFFICE, supra note 3; Taylor,
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APPENDIX A

1. Please indicate whether you agree or disagree:
Patent eligibility is an important consideration when your firm decides
whether to invest in a company developing technology.
Strongly agree
Somewhat agree
Neither agree nor disagree
Somewhat disagree
Strongly disagree
2. Please indicate whether you agree or disagree:
If the law of patent eligibility makes patents unavailable for a technology,
your firm is less likely to invest in a company developing that technology.
Strongly agree
Somewhat agree
Neither agree nor disagree
Somewhat disagree
Strongly disagree
3. Please indicate whether you agree or disagree:
If the law of patent eligibility makes patents more difficult to obtain for a
technology, your firm is less likely to invest in a company developing that
technology.
Strongly agree
Somewhat agree
Neither agree nor disagree
Somewhat disagree
Strongly disagree
4. What factors does your firm rely upon when deciding whether to invest
in a company developing technology? Please rank the following factors in
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order of priority, with the most important at the top. (You may drag and
drop the factors to re-order them.)
Quality of the company's technology
Availability of U.S. patent protection given U.S.
patent eligibility
Availability of foreign patent protection given
foreign patent eligibility
Availability of copyright protection
Availability of trade secret protection

First mover advantage
Quality of the company's people
Size of the potential market for the technology
Other
5. For each industry in which your firm invests, please indicate how the
elimination of patents would affect your firm's decision whether to invest
in a company developing technology in that industry (you should skip
industries in which your firm does not invest):

Strongly
inesen

investment
Software,
Internet
Computer and
other electronic

hardware
Semiconductor
Pharmaceutical

increase

Somewhat

Strongly

No

decrease

decrease

investment

impact

investment

investment

Somewhat
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Medical devices,
methods, and
other medical
Biotechnology
Communications
Transportation
(including
automotive)
Construction
Energy
Other (please
specify)

6. For each industry in which your firm invests, please indicate how a
decreased availability of patents would affect your firm's decision
whether to invest in a company developing technology in that industry
(you should skip industries in which your firm does not invest):

Somewhat
Strongly
investment
Software,
Internet
Computer and
other electronic

hardware
Semiconductor
Pharmaceutical

Medical devices,
methods, and
other medical
Biotechnology
Communications
Transportation
(including
automotive)
Construction

increase
investment

No

Somewhat

Strongly

decrease

decrease

investment

investment
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Energy
Other (please
specify)

The Supreme Court has decided four cases in the past seven years on the
issue of patent eligibility:lsE]
"
"

"

Bilski v. Kappos (2010) (finding a method of hedging risk to be
patent ineligible);
Mayo Collaborative Services v. Prometheus Labs, Inc. (2012)
(finding a method for identifying effective drug doses to be patent
ineligible);
Association for Molecular Pathology v. Myriad Genetics, Inc.

(2013) (finding isolated DNA to be patent ineligible but cDNA to
be patent eligible); and
"

Alice Corp. v. CLS Bank Int'l (2014) (finding a computer-

implemented method of intermediated settlement to be patent
ineligible).
7. Are you familiar with one or more of these decisions?
Yes
No

[If "No" was selected in response to Question 7, the survey skipped to
Question 15.]
8. Has the effect of these decisions on your firm's existing investments
been positive or negative?
Very positive
Somewhat positive
No impact
Somewhat negative
Very negative
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9. Have any of these Supreme Court decisions affected your firm's
decisions whether to invest in companies?
Yes
No
Don't know

[If "No" or "Don'tknow" was selected in response to Question 9, the survey
skipped to Question 15.]
10. Which decisions affected your firm's decisions whether to invest in
companies? (You may select more than one.)
Bilski v. Kappos (2010)
Mayo Collaborative Services v. Prometheus Labs., Inc. (2012)
Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)
Alice Corp. v. CLS Bank Int'l (2014)
11. How have the cases you selected affected your firm's decisions
whether to invest in companies? (You may select more than one.)
Increased investments overall
Decreased investments overall

Shifted investments between industries
Other (please specify)

[If the answer to Question 11 included "Shifted investments between
industries,"the survey presented Questions 12 and 13.]
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You indicated your firm has shifted investments between industries.
12. Out of which industries have you shifted investments (you may select
more than one)?
Software, Internet
Computer and other electronic hardware

Semiconductor
Pharmaceutical

Medical devices, methods, and other medical
Biotechnology
Communications
Transportation (including automotive)
Construction
Energy
Other (please specify)

13. Into which industries have you shifted financing (you may select more
than one)?
Software, Internet
Computer and other electronic hardware

Semiconductor
Pharmaceutical

Medical devices, methods, and other medical
Biotechnology
Communications
Transportation (including automotive)
Construction
Energy
Other (please specify)
14. If you are willing, please describe examples of how any of the Supreme
Court's decisions on patent eligibility in the last seven years have affected
your firm's decisions on how to invest in companies. You can skip this
question if you would rather.

[If "Yes" was selected in response to Question 7, at this point the survey
skipped to Question 22.]
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15. Since 2009, how have your firm's investments in companies changed
(you may select more than one)?
No change
Increased investments overall
Decreased investments overall

Shifted investments between industries
Other (please specify)
[If "No change" was selected in response to Question 15, the survey

presented Question 16.]
16. Has a decreased availability of patents since 2009 contributed to your
firm's lack of change in investments?
Yes
No
Don't know

[If "Increasedinvestments overall" was selected in response to Question 15,
the survey presented Question 17.]
17. Has a decreased availability of patents since 2009 contributed to your
firm's increased investments?
Yes
No
Don't know

[If "Decreasedinvestments overall" was selected in response to Question 15,
the survey presented Question 18.]
18. Has a decreased availability of patents since 2009 contributed to your
firm's decreased investments?
Yes
No
Don't know

[If "Shifted investments between industries" was selected in response to
Question 15, the survey presented Questions 19-21.]
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You indicated your firm has shifted investments between industries.
19. Has a decreased availability of patents since 2009 contributed to your
firm's shifting of investments between industries?
Yes
No
Don't know
20. Out of which industries have you shifted investments (you may select
more than one)?
Software, Internet
Computer and other electronic hardware

Semiconductor
Pharmaceutical

Medical devices, methods, and other medical
Biotechnology
Communications
Transportation (including automotive)
Construction
Energy
Other (please specify)

21. Into which industries have you shifted financing (you may select more
than one)?
Software, Internet
Computer and other electronic hardware

Semiconductor
Pharmaceutical

Medical devices, methods, and other medical
Biotechnology
Communications
Transportation (including automotive)
Construction
Energy
Other (please specify)
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22. Are you willing to engage in a short telephone interview at a later date?
Yes
No

CARDOZO LAW REVIEW

2104

[Vol. 41:2019

APPENDIX B

Table 1: Investment Stages of Respondents' Firms
Stage

Percent

Early Stage

59%

Seed Stage

45%

Middle Stage

27%

Growth Stage
Expansion Stage
Late Stage

22%
15%
1%

Table 2: Investment Industries of Respondents' Firms
Industry

Percent

Software and the Internet
Medical Devices
Computer Electronics/Hardware

70%
63%
61%

Biotechnology

55%

Pharmaceutical
Communications

54%
53%

Energy
Semiconductors

49%
48%

Transportation
Construction

47%
42%
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Table 3: Investment Focus of Respondents' Firms
Firm Focus
Information Technology
Life Sciences & Healthcare
Software & the Internet
Manufacturing & Industrial
Business Services
Communications & Networking
Energy & Clean Tech

Percent
62%
46%
40%
25%
23%
20%
19%

Media & Digital Media

17%

Consumer Products & Services
Financial Services
Medical Devices
Transportation & Distribution
Retail & Restaurant
Food & Agriculture
Real Estate & Construction
Semiconductors
Sports & Entertainment
Education & Training
Defense & Homeland Security
Storage & Hardware
Electronics & Advanced Materials

16%
15%
15%
10%
9%
5%
5%
4%
4%
3%
3%
3%
2%

Table 4: Familiarity with at Least One Eligibility Case
Type

Percent

Familiar

38%

Unfamiliar

62%

Table 5: Investment Stages of Firms: Resp's v. Non-Resp's

Stage
Early Stage

Resp's
59%

Non-Resp's
49%

Seed Stage

45%

30%

Middle Stage

27%
22%
15%
1%

46%
22%
20%
3%

Growth Stage

Expansion Stage
Late Stage
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Table 6: Investment Focus of Firms: Resp's v. Non-Resp's
Firm Focus

Resp's

Non-Resp's

Information Technology

62%
46%
40%
25%
23%
20%
19%
17%
16%
15%
15%
10%

55%
43%
32%
32%
33%
22%
23%

Life Sciences & Healthcare
Software & the Internet
Manufacturing & Industrial

Business Services
Communications & Networking
Energy & Clean Tech

Media & Digital Media
Consumer Products & Services

Financial Services
Medical Device
Transportation & Distribution
Retail & Restaurant
Food & Agriculture
Real Estate & Construction

Semiconductors
Sports & Entertainment
Education & Training

Defense & Homeland Security
Storage & Hardware

Electronics & Advanced Materials

Table 7:

9%
5%
5%
4%
4%
3%
3%
3%
2%

21%

24%
16%
13%
14%
11%
4%
6%
4%
5%
6%
5%
3%

1%

Patent Eligibility Is an Important Consideration in Firm
Decisions Whether to Invest in Companies Developing
Technology

Response
Strongly agree

Percent

Somewhat disagree

43%
31%
13%
9%

Strongly disagree

5%

Somewhat agree
Neither agree nor disagree
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Less Likely to Invest if Patent Eligibility Makes Patents

Unavailable
Response

Percent

Strongly agree
Somewhat agree
Neither agree nor disagree
Somewhat disagree

23%
39%
19%
13%

Strongly disagree

7%

Table 9:

Less Likely to Invest if Patent Eligibility Makes Patents
More Difficult to Obtain

Response
Strongly agree

Percent
19%

Somewhat agree
Neither agree nor disagree

40%
18%

Somewhat disagree
Strongly disagree

17%
5%

Table 10: Importance of Patent Eligibility by Investment Stage
Stage

Mean (1-5 Scale)

Seed
Early
Middle
Growth
Expansion
Late

3.95
3.98
3.95
3.84
3.88
3.80
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Table 11: Importance of Patent Eligibility by Industry
Industry

Mean (1-5 Scale)

Medical Devices

4.17

Biotechnology
Pharmaceutical
Energy
Semiconductors

4.13
4.13
4.07
4.04

Construction

4.01

Computer Electronics/Hardware
Transportation
Communications
Software and the Internet

3.99
3.99
3.98
3.92

Table 12: Patent Eligibility Importance By Industry

Percent

Strongly or Somewhat Agreeing Patent Eligibility Is an
Important Consideration in Firm Decisions Whether to
Invest in Companies Developing Technology
Industry
Medical Devices
Biotechnology

Percent
81%
79%

Pharmaceutical
Energy

79%
78%

Semiconductors
Construction

76%
76%

Computer Electronics/Hardware

75%

Transportation

75%

Communications

74%

Software and the Internet

72%
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Table 13: Importance of Patent Eligibility by Familiarity with at
Least One Eligibility Case
Type

Mean (1-5 Scale)

Familiar

4.18
3.93

Unfamiliar
Table 14: Factors

Relied upon when

Deciding

to Invest in

Companies Developing Technology: Ranking (1-5 of 9)
Factor

1st

2nd

3rd

4th

5th

Quality of People
Quality of Technology
Size of Potential Market

48%
24%
19%

23%
31%
33%

14%
30%
26%

5%
10%
12%

3%
3%
3%

First-Mover Advantage

2%

5%

13%

29%

14%

Avail. of U.S. Patents

2%

4%

10%

27%

34%

Avail. of Trade Secrets
Avail. of Foreign Patents

0%
0%

1%
1%

2%
2%

5%
5%

17%
17%

Avail. of Copyrights

0%

0%

1%

4%

7%

Other

4%

3%

3%

4%

2%

Table 15: Factors Relied

upon when

Deciding

to Invest in

Companies Developing Technology: Weighted Mean
Factor

Mean (1-9 Scale)

Quality of People
Quality of Technology
Size of Potential Market

7.77
7.55
7.24
5.31
4.94
3.72
3.31
3.13
2.03

Avail. of U.S. Patents
First-Mover Advantage
Avail. of Foreign Patents

Avail. of Trade Secrets
Avail. of Copyrights
Other
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Table 16: Importance of Availability

of U.S.
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Patents when

Deciding to Invest in Companies Developing
Technology: Weighted Mean (By Industry)
Industry

Mean (1-9 Scale)

Medical Devices
Pharmaceutical
Biotechnology
Energy
Other
Semiconductors

5.42
5.42
5.41
5.36
5.35
5.31
5.31
5.26
5.26
5.24
5.18

Construction
Transportation
Communications
Computers
Software and the Internet

Table 17: Impact of Elimination of Patents
Decisions: Weighted Mean

on Investment

Industry

Mean (1-5 Scale)

Construction

2.82

Software and the Internet
Transportation

2.74
2.67

Communications
Energy

2.61
2.50

Computer/Electronic Hardware
Semiconductors

2.39
2.23

Medical Devices
Biotechnology

1.89
1.83

Pharmaceutical

1.80
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of Elimination

of Patents

2111

on Investment

Decisions: Responses
Strongly Somewhat

Industry
Construc tion
Soft. &t he Internet
Transpor tation
Commut ications

Energy
Comp.E lecs. Hard.
Semicon ductors
Medical Devices
Bioteclu Lology
Pharmac eutical

No

Somewhat Strongly

Increase Increase Impact Decrease Decrease
1%
5%
75%
14%
6%
3%
2%
2%

10%

53%

8%

48%

27%
31%
32%

7%

53%

8%

2%
4%

4%
6%

49%
33%

30%
39%

15%
18%

4%

3%

33%

34%

27%

6%
7%
7%

3%
2%
1%

11%
14%
19%

32%
22%
11%

47%
55%
62%

Table 19: Impact of Decreased Availability of
Investment Decisions: Weighted Mean
Industry
Construction
Transportation

Software and the Internet
Communications
Energy
Computer/Electronic Hardware

Semiconductors
Medical Devices

Biotechnology
Pharmaceutical

Mean 1-5 Scale)

2.78
2.62
2.59
2.54
2.47
2.26
2.09
1.83
1.78
1.70

7%

10%

Patents on
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Table 20: Impact of Decreased Availability
Investment Decisions: Responses
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of

Patents

on

Strongly Somewhat No Somewhat Strongly
Industry
Increase Increase Impact Decrease Decrease
21%
3%
Construction
1%
3%
71%
Transportation
2%
5%
54%
32%
7%
Soft. & the Internet 1%
6%
53%
30%
9%

Communications
Energy

Comp./Elecs. Hard.
Semiconductors
Medical Devices
Biotechnology
Pharmaceutical

1%
2%
2%
1%
1%
3%
3%

5%
4%
4%
2%
3%
2%
1%

52%
48%
33%
30%
14%
17%
14%

31%
33%
40%
40%
40%
29%
25%

11%
13%
21%
27%
42%
50%
56%

Table 21: Impact of Supreme Court's Eligibility Cases on Existing
Investments
Response
Very positive

Percent
1%

Somewhat positive

13%
46%
33%
7%

No Impact

Somewhat negative
Very negative

Table 22: Have Any of the Supreme Court's Eligibility Cases
Affected Firm Decisions Whether to Invest in
Companies
Response
Yes
No
Don't know

Percent
33%
61%

6%
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Table 23: Respondents Indicating the Supreme Court's Eligibility
Cases Have Affected Firm Decisions Whether to Invest
in Companies, by Industry

Industries
Pharmaceutical

Percent
39%

Medical Devices
Semiconductors
Biotechnology
Transportation
Communications

38%
38%
37%
36%
35%

Computer/Electronic Hardware
Construction
Energy
Software and the Internet

34%
34%
33%
32%

Table 24: Which of the Supreme Court's Eligibility Cases Affected
Firm Decisions Whether to Invest in Companies
Response

Percent

Ass'n for Molecular Pathology v. Myriad

38%

Mayo v. Prometheus

29%

Alice v. CLS Bank
Bilski v. Kappos

20%
13%

Table 25: How Have the Cases You Selected Affected Firm
Decisions Whether to Invest in Companies
Response
Decreased investments overall
Shifted investments between industries
Increased investments overall

Percent
49%
34%
8%

Other

9%
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Table 26: Investments Shifted Away from These Industries

Industries
Pharmaceutical
Biotechnology

Percent
26%
24%

Medical Devices

21%

Software and the Internet
Communications

21%
6%

Computer/Electronic Hardware
Construction
Transportation
Energy

3%
0%
0%
0%

Semiconductors

0%

Table 27: Investments Shifted into These Industries
Industries
Computer/Electronic Hardware
Energy
Medical Devices
Software and the Internet
Pharmaceutical
Biotechnology
Semiconductors
Construction
Communications
Transportation

Percent
16%
16%
13%
13%
6%
6%
6%
3%
3%
0%

Table 28: Has Decreased Availability of Patents Since 2009
Contributed to Your Firm's Change in Investments
(Unknowledgeable Investors Only)
Type of Change

Yes

No Change

2%

Inc'd investments overall
Dec'd investments overall

0%
14%

Shifted investments b/w industries

4%

No
95%
88%
82%
84%

Don't Know
4%

12%
5%
12%
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Table 29: Eligibility

Unknowledgeable

Investors
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Shifted

Investments Away from These Industries

Industries

Percent

Energy

17%

Semiconductors
Pharmaceutical

12%
11%

Medical Devices
Biotechnology

11%
10%

Communications
Computer/Electronic Hardware

10%
10%

Software and the Internet
Construction

7%
3%

Transportation

2%

Table 30: Eligibility
Unknowledgeable
Investments into These Industries

Investors

Industries

Percent

Software and the Internet

32%

Computer/Electronic Hardware

11%

Transportation
Medical Devices
Communications
Biotechnology
Energy
Pharmaceutical

11%
10%
8%
5%

5%
3%

Construction

3%

Semiconductors

2%

Table 31: Eligibility

Knowledgeable

Investors'

Positive or Negative

Characterization
Positive
Negative
Other

Shifted

Percent
13%
83%
4%

Comments:
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Table 32: Eligibility Knowledgeable
Percent by Industry
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Investors'

Industries
Software and the Internet
Biotechnology
Pharmaceutical
Medical Devices

Percent
35%
30%
13%
0%

Semiconductors

Construction.

0%
0%
0%
0%
0%

Energy
Generalized

0%
35%

Transportation
Communications
Computer/Electronic Hardware

Table 33: Eligibility Knowledgeable Investors'
Percent Positive and Negative by Industry
Industries
Software and the Internet
Biotechnology
Pharmaceutical
Medical Devices
Semiconductors
Transportation
Communications
Computer/Electronic Hardware
Construction
Energy

Positive

Generalized

25%
14%
0%
0%
0%

Comments:

Comments:

Negative
63%
86%
100%
0%

0%

0%

0%

0%
0%
0%

0%
0%
0%
0%

0%

100%

0%

